| 1 |
Azacitidine FDA Label
|
| 2 |
Bexarotene FDA Label
|
| 3 |
Bortezomib FDA Label
|
| 4 |
Carfilzomib FDA Label
|
| 5 |
SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity. Front Immunol. 2022 Oct 10;13:989895.
|
| 6 |
Cisplatin FDA Label
|
| 7 |
Clofarabine FDA Label
|
| 8 |
Cyclophosphamide FDA Label
|
| 9 |
Cytarabine FDA Label
|
| 10 |
Dasatinib FDA Label
|
| 11 |
Defibrotide FDA Label
|
| 12 |
A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
|
| 13 |
Dexamethasone FDA Label
|
| 14 |
Doxorubicin FDA Label
|
| 15 |
Etodolac FDA Label
|
| 16 |
Etoposide FDA Label
|
| 17 |
Everolimus FDA Label
|
| 18 |
ClinicalTrials.gov (NCT04270409) Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma. U.S. National Institutes of Health.
|
| 19 |
Lenalidomide FDA Label
|
| 20 |
Leuprolide FDA Label
|
| 21 |
Melphalan FDA Label
|
| 22 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| 23 |
Panobinostat FDA Label
|
| 24 |
Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation. Ann Hematol. 2023 Jul;102(7):1915-1925.
|
| 25 |
Pomalidomide FDA Label
|
| 26 |
Prednisone FDA Label
|
| 27 |
Sirolimus FDA Label
|
| 28 |
Succinylcholine FDA Label
|
| 29 |
Tadalafil FDA Label
|
| 30 |
Thalidomide FDA Label
|
| 31 |
Vincristine FDA Label
|
| 32 |
Integrative medicine in multiple myeloma and plasma cell disorders. Complement Ther Med. 2023 May;73:102939.
|
| 33 |
Vorinostat FDA Label
|
| 34 |
Belinostat FDA Label
|
| 35 |
ClinicalTrials.gov (NCT03338972) Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
|
| 36 |
ClinicalTrials.gov (NCT03502577) BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple Myeloma
|
| 37 |
ClinicalTrials.gov (NCT03710421) CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
| 38 |
ClinicalTrials.gov (NCT04000282) First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
|
| 39 |
Treatment of renal failure associated with multiple myeloma and other diseases by PACAP-38.Ann N Y Acad Sci. 2006 Jul;1070:1-4. doi: 10.1196/annals.1317.093.
|
| 40 |
Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells.Exp Hematol. 2015 Nov;43(11):951-962.e3. doi: 10.1016/j.exphem.2015.07.005. Epub 2015 Aug 6.
|
| 41 |
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.Blood. 2016 Apr 14;127(15):1896-906. doi: 10.1182/blood-2015-08-665679. Epub 2016 Jan 11.
|
| 42 |
Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.Oncotarget. 2015 Aug 21;6(24):20621-35. doi: 10.18632/oncotarget.4139.
|
| 43 |
Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis.Leukemia. 2002 Jan;16(1):127-34. doi: 10.1038/sj.leu.2402328.
|
| 44 |
TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma.Int J Cancer. 2009 Oct 15;125(8):1985-91. doi: 10.1002/ijc.24431.
|
| 45 |
Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.Blood. 2010 Apr 29;115(17):3541-52. doi: 10.1182/blood-2009-09-243535. Epub 2010 Jan 6.
|
| 46 |
The expression of BST2 in human and experimental mouse brain tumors.Exp Mol Pathol. 2011 Aug;91(1):440-6. doi: 10.1016/j.yexmp.2011.04.012. Epub 2011 May 1.
|
| 47 |
Gene expression profile of multiple myeloma cell line treated by realgar.J Exp Clin Cancer Res. 2006 Jun;25(2):243-9.
|
| 48 |
TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma.Oncotarget. 2018 Apr 6;9(26):18480-18493. doi: 10.18632/oncotarget.24883. eCollection 2018 Apr 6.
|
| 49 |
Control of autophagic cell death by caspase-10 in multiple myeloma.Cancer Cell. 2013 Apr 15;23(4):435-49. doi: 10.1016/j.ccr.2013.02.017. Epub 2013 Mar 28.
|
| 50 |
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.Leukemia. 2016 Feb;30(2):409-16. doi: 10.1038/leu.2015.259. Epub 2015 Sep 30.
|
| 51 |
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction.Blood. 2004 Dec 1;104(12):3722-30. doi: 10.1182/blood-2004-02-0474. Epub 2004 Aug 12.
|
| 52 |
CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy.Haematologica. 2006 Nov;91(11):1577-8. Epub 2006 Oct 17.
|
| 53 |
Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.Blood. 2007 Feb 1;109(3):1185-92. doi: 10.1182/blood-2006-07-034017. Epub 2006 Oct 12.
|
| 54 |
Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001.Oncotarget. 2018 Dec 28;9(102):37700-37714. doi: 10.18632/oncotarget.26491. eCollection 2018 Dec 28.
|
| 55 |
CTLA4Ig-based reduced intensity conditioning and donor lymphocyte infusions for haploidentical transplantation in refractory aggressive B-cell lymphoma relapsing after an autograft: Early results from a pilot study.Exp Hematol. 2019 Sep;77:26-35.e1. doi: 10.1016/j.exphem.2019.08.002. Epub 2019 Aug 23.
|
| 56 |
Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma.Br J Haematol. 2015 Nov;171(3):387-99. doi: 10.1111/bjh.13596. Epub 2015 Jul 20.
|
| 57 |
EphA4 promotes cell proliferation and cell adhesion-mediated drug resistance via the AKT pathway in multiple myeloma.Tumour Biol. 2017 Mar;39(3):1010428317694298. doi: 10.1177/1010428317694298.
|
| 58 |
Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.Clin Cancer Res. 2011 Dec 15;17(24):7776-84. doi: 10.1158/1078-0432.CCR-11-1791. Epub 2011 Oct 12.
|
| 59 |
Defining the role of TORC1/2 in multiple myeloma.Blood. 2011 Dec 22;118(26):6860-70. doi: 10.1182/blood-2011-03-342394. Epub 2011 Nov 1.
|
| 60 |
Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma.Cancer Epidemiol. 2009 Oct;33(3-4):276-80. doi: 10.1016/j.canep.2009.08.005. Epub 2009 Sep 6.
|
| 61 |
CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity.Cancer Chemother Pharmacol. 2014 Mar;73(3):651-5. doi: 10.1007/s00280-014-2409-9. Epub 2014 Feb 12.
|
| 62 |
Triptolide induces apoptotic cell death of multiple myeloma cells via transcriptional repression of Mcl-1.Int J Oncol. 2014 Apr;44(4):1131-8. doi: 10.3892/ijo.2014.2280. Epub 2014 Jan 27.
|
| 63 |
Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region.BMC Cancer. 2015 Feb 18;15:68. doi: 10.1186/s12885-015-1078-3.
|
| 64 |
JAM-A as a prognostic factor and new therapeutic target in multiple myeloma.Leukemia. 2018 Mar;32(3):736-743. doi: 10.1038/leu.2017.287. Epub 2017 Sep 28.
|
| 65 |
C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis.Sci Signal. 2017 Dec 12;10(509):eaan6282. doi: 10.1126/scisignal.aan6282.
|
| 66 |
High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma.PLoS One. 2017 Jul 20;12(7):e0181487. doi: 10.1371/journal.pone.0181487. eCollection 2017.
|
| 67 |
Image of the Month: Multifocal 68Ga Prostate-Specific Membrane Antigen Ligand Uptake in the Skeleton in a Man With Both Prostate Cancer and Multiple Myeloma.Clin Nucl Med. 2017 Jul;42(7):547-548. doi: 10.1097/RLU.0000000000001649.
|
| 68 |
Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6.J Biol Chem. 2017 Mar 10;292(10):4280-4292. doi: 10.1074/jbc.M116.733030. Epub 2017 Jan 31.
|
| 69 |
Hypoxia-inducible factor (HIF)-1 suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.Leukemia. 2013 Aug;27(8):1697-706. doi: 10.1038/leu.2013.24. Epub 2013 Jan 24.
|
| 70 |
IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the rna-binding protein hnRNP A1.J Biol Chem. 2011 Jan 7;286(1):67-78. doi: 10.1074/jbc.M110.153221. Epub 2010 Oct 25.
|
| 71 |
Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.J Clin Invest. 2018 Jun 1;128(6):2487-2499. doi: 10.1172/JCI88169. Epub 2018 May 14.
|
| 72 |
IB kinase (IKBKB) mutations in lymphomas that constitutively activate canonical nuclear factor B (NFB) signaling.J Biol Chem. 2014 Sep 26;289(39):26960-26972. doi: 10.1074/jbc.M114.598763. Epub 2014 Aug 8.
|
| 73 |
The role of IL-21 in hematological malignancies.Cytokine. 2011 Nov;56(2):133-9. doi: 10.1016/j.cyto.2011.07.011. Epub 2011 Aug 6.
|
| 74 |
Genomic studies of multiple myeloma reveal an association between X chromosome alterations and genomic profile complexity.Genes Chromosomes Cancer. 2017 Jan;56(1):18-27. doi: 10.1002/gcc.22397. Epub 2016 Aug 18.
|
| 75 |
Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma.Sci Transl Med. 2016 Aug 24;8(353):353ra113. doi: 10.1126/scitranslmed.aad8949.
|
| 76 |
Hypoxia-inducible KDM3A addiction in multiple myeloma.Blood Adv. 2018 Feb 27;2(4):323-334. doi: 10.1182/bloodadvances.2017008847.
|
| 77 |
Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma.Hematology. 2005;10 Suppl 1:117-26. doi: 10.1080/10245330512331390140.
|
| 78 |
Comparable gene structure of the immunoglobulin heavy chain variable region between multiple myeloma and normal bone marrow lymphocytes.Leukemia. 1996 Nov;10(11):1804-12.
|
| 79 |
PGC1 regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism.Mol Oncol. 2018 Sep;12(9):1579-1595. doi: 10.1002/1878-0261.12363. Epub 2018 Aug 14.
|
| 80 |
Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma.Leuk Res. 2008 Oct;32(10):1499-504. doi: 10.1016/j.leukres.2008.03.001. Epub 2008 Apr 10.
|
| 81 |
Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.PLoS One. 2011;6(11):e27707. doi: 10.1371/journal.pone.0027707. Epub 2011 Nov 16.
|
| 82 |
Cancer-testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple Myeloma.Br J Haematol. 2015 Dec;171(5):752-62. doi: 10.1111/bjh.13762. Epub 2015 Oct 12.
|
| 83 |
TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.Blood Adv. 2017 Oct 26;1(24):2124-2137. doi: 10.1182/bloodadvances.2017008813. eCollection 2017 Nov 14.
|
| 84 |
The effect of S1P receptor signaling pathway on the survival and drug resistance in multiple myeloma cells.Mol Cell Biochem. 2017 Jan;424(1-2):185-193. doi: 10.1007/s11010-016-2854-3. Epub 2016 Oct 27.
|
| 85 |
Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.Haematologica. 2018 Feb;103(2):325-335. doi: 10.3324/haematol.2017.172973. Epub 2017 Nov 9.
|
| 86 |
Mesenchymal stem cells secretomes' affect multiple myeloma translation initiation.Cell Signal. 2016 Jun;28(6):620-30. doi: 10.1016/j.cellsig.2016.03.003. Epub 2016 Mar 11.
|
| 87 |
Serum miR-30d as a novel biomarker for multiple myeloma and its antitumor role in U266 cells through the targeting of the MTDH/PI3K/Akt signaling pathway.Int J Oncol. 2018 Nov;53(5):2131-2144. doi: 10.3892/ijo.2018.4532. Epub 2018 Aug 21.
|
| 88 |
A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts.PLoS One. 2015 Jan 24;10(1):e0116135. doi: 10.1371/journal.pone.0116135. eCollection 2015.
|
| 89 |
Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma.Br J Haematol. 2017 Aug;178(4):534-546. doi: 10.1111/bjh.14707. Epub 2017 Apr 25.
|
| 90 |
Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.Ann Hematol. 2011 Sep;90(9):1037-45. doi: 10.1007/s00277-011-1193-4. Epub 2011 Feb 22.
|
| 91 |
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.Clin Cancer Res. 2017 Sep 1;23(17):5225-5237. doi: 10.1158/1078-0432.CCR-17-0263. Epub 2017 Apr 25.
|
| 92 |
Semaphorin-3A inhibits multiple myeloma progression in a mouse model.Carcinogenesis. 2018 Oct 8;39(10):1283-1291. doi: 10.1093/carcin/bgy106.
|
| 93 |
BSG and MCT1 Genetic Variants Influence Survival in Multiple Myeloma Patients.Genes (Basel). 2018 Apr 24;9(5):226. doi: 10.3390/genes9050226.
|
| 94 |
Expression and prognostic significance of Oct2 and Bob1 in multiple myeloma: implications for targeted therapeutics.Leuk Lymphoma. 2011 Apr;52(4):659-67. doi: 10.3109/10428194.2010.548535. Epub 2011 Jan 11.
|
| 95 |
Significant biological role of sp1 transactivation in multiple myeloma.Clin Cancer Res. 2011 Oct 15;17(20):6500-9. doi: 10.1158/1078-0432.CCR-11-1036. Epub 2011 Aug 19.
|
| 96 |
Recombinant human thrombopoietin improves the efficacy of intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor in mobilizing peripheral blood stem cells in patients with multiple myeloma: A cohort study.Medicine (Baltimore). 2017 Dec;96(50):e9302. doi: 10.1097/MD.0000000000009302.
|
| 97 |
8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma.Med Oncol. 2013 Jun;30(2):489. doi: 10.1007/s12032-013-0489-8. Epub 2013 Feb 20.
|
| 98 |
APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.Leukemia. 2019 Feb;33(2):426-438. doi: 10.1038/s41375-018-0242-6. Epub 2018 Aug 22.
|
| 99 |
LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens.Front Immunol. 2018 Oct 23;9:2459. doi: 10.3389/fimmu.2018.02459. eCollection 2018.
|
| 100 |
TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF- inhibition.Cell Cycle. 2016;15(4):559-72. doi: 10.1080/15384101.2015.1136038.
|
| 101 |
Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop.Sci Rep. 2019 Mar 1;9(1):3245. doi: 10.1038/s41598-019-39672-7.
|
| 102 |
The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors.Cell Death Dis. 2019 Apr 11;10(4):324. doi: 10.1038/s41419-019-1562-9.
|
| 103 |
High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens.J Cancer. 2019 Jun 2;10(14):3239-3245. doi: 10.7150/jca.30102. eCollection 2019.
|
| 104 |
Clinical effects of CD33 and MPC-1 on the prognosis of multiple myeloma treated with bortezomib.Leuk Lymphoma. 2019 Sep;60(9):2152-2157. doi: 10.1080/10428194.2019.1574003. Epub 2019 Mar 19.
|
| 105 |
Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?.Dis Markers. 2019 Jan 27;2019:1806034. doi: 10.1155/2019/1806034. eCollection 2019.
|
| 106 |
Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients.Cancers (Basel). 2019 Mar 6;11(3):321. doi: 10.3390/cancers11030321.
|
| 107 |
Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.Br J Haematol. 2019 Feb;184(4):578-593. doi: 10.1111/bjh.15669. Epub 2018 Nov 8.
|
| 108 |
Inhibition of the FAD containing ER oxidoreductin 1 (Ero1) protein by EN-460 as a strategy for treatment of multiple myeloma.Bioorg Med Chem. 2019 Apr 15;27(8):1479-1488. doi: 10.1016/j.bmc.2019.02.016. Epub 2019 Feb 10.
|
| 109 |
Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma.Front Oncol. 2019 Aug 8;9:722. doi: 10.3389/fonc.2019.00722. eCollection 2019.
|
| 110 |
Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenstrm Macroglobulinemia.Clin Cancer Res. 2019 Jan 1;25(1):369-377. doi: 10.1158/1078-0432.CCR-18-1776. Epub 2018 Sep 11.
|
| 111 |
The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation.Leukemia. 2020 Jan;34(1):257-270. doi: 10.1038/s41375-019-0486-9. Epub 2019 May 31.
|
| 112 |
Ferroportin downregulation promotes cell proliferation by modulating the Nrf2-miR-17-5p axis in multiple myeloma.Cell Death Dis. 2019 Aug 19;10(9):624. doi: 10.1038/s41419-019-1854-0.
|
| 113 |
The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma.Cancers (Basel). 2019 Nov 20;11(12):1823. doi: 10.3390/cancers11121823.
|
| 114 |
Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.JCI Insight. 2019 Jun 13;5(14):e125932. doi: 10.1172/jci.insight.125932.
|
| 115 |
Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15.PLoS One. 2019 Oct 22;14(10):e0223807. doi: 10.1371/journal.pone.0223807. eCollection 2019.
|
| 116 |
ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR).Ann Hematol. 2017 May;96(5):847-858. doi: 10.1007/s00277-017-2949-2. Epub 2017 Feb 25.
|
| 117 |
Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3.Cancer Res. 2017 Mar 15;77(6):1283-1295. doi: 10.1158/0008-5472.CAN-15-3545. Epub 2017 Mar 2.
|
| 118 |
STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models.Oncotarget. 2018 Jul 31;9(59):31367-31379. doi: 10.18632/oncotarget.25825. eCollection 2018 Jul 31.
|
| 119 |
The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains.Oncotarget. 2017 Oct 20;8(61):103731-103743. doi: 10.18632/oncotarget.21909. eCollection 2017 Nov 28.
|
| 120 |
The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells In Vitro and In Vivo.Clin Cancer Res. 2019 Oct 15;25(20):6195-6205. doi: 10.1158/1078-0432.CCR-18-3788. Epub 2019 Jul 29.
|
| 121 |
Characterizing the Tumor Suppressor Role of CEACAM1 in Multiple Myeloma.Cell Physiol Biochem. 2018;45(4):1631-1640. doi: 10.1159/000487730. Epub 2018 Feb 21.
|
| 122 |
Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma.Blood Adv. 2019 Apr 9;3(7):995-1002. doi: 10.1182/bloodadvances.2018028456.
|
| 123 |
DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.Haematologica. 2019 Jan;104(1):155-165. doi: 10.3324/haematol.2018.191262. Epub 2018 Aug 31.
|
| 124 |
DPP8 is a novel therapeutic target for multiple myeloma.Sci Rep. 2019 Dec 2;9(1):18094. doi: 10.1038/s41598-019-54695-w.
|
| 125 |
DUSP facilitates RPMI8226 myeloma cell aging and inhibited TLR4 expression.Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):6030-6034. doi: 10.26355/eurrev_201809_15939.
|
| 126 |
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.Proc Natl Acad Sci U S A. 2019 Dec 3;116(49):24881-24891. doi: 10.1073/pnas.1912033116. Epub 2019 Nov 21.
|
| 127 |
A Minimal Physiologically-Based Pharmacokinetic Model Demonstrates Role of the Neonatal Fc Receptor (FcRn) Competition in Drug-Disease Interactions With Antibody Therapy.Clin Pharmacol Ther. 2020 Feb;107(2):423-434. doi: 10.1002/cpt.1619. Epub 2019 Sep 25.
|
| 128 |
Expression of functional folate receptors in multiple myeloma.Leuk Lymphoma. 2018 Dec;59(12):2982-2989. doi: 10.1080/10428194.2018.1453066. Epub 2018 Apr 4.
|
| 129 |
MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.Leukemia. 2019 Mar;33(3):739-748. doi: 10.1038/s41375-018-0300-0. Epub 2018 Nov 23.
|
| 130 |
LINC01234 promotes multiple myeloma progression by regulating miR-124-3p/GRB2 axis.Am J Transl Res. 2019 Oct 15;11(10):6600-6618. eCollection 2019.
|
| 131 |
Emerging drug development technologies targeting ubiquitination for cancer therapeutics.Pharmacol Ther. 2019 Jul;199:139-154. doi: 10.1016/j.pharmthera.2019.03.003. Epub 2019 Mar 7.
|
| 132 |
Long Non-Coding RNA MEG3 Functions as a Competing Endogenous RNA to Regulate HOXA11 Expression by Sponging miR-181a in Multiple Myeloma.Cell Physiol Biochem. 2018;49(1):87-100. doi: 10.1159/000492846. Epub 2018 Aug 22.
|
| 133 |
Serum and urinary levels of CD222 in cancer: origin and diagnostic value.Neoplasma. 2018 Sep 19;65(5):762-768. doi: 10.4149/neo_2018_171203N792. Epub 2018 Jun 18.
|
| 134 |
Polymorphism of IL-10 receptor affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.Hematol Oncol. 2017 Dec;35(4):711-718. doi: 10.1002/hon.2322. Epub 2016 Jul 13.
|
| 135 |
Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma.Leukemia. 2020 Feb;34(2):567-577. doi: 10.1038/s41375-019-0558-x. Epub 2019 Aug 28.
|
| 136 |
Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.Cancer Immunol Immunother. 2018 Jun;67(6):861-872. doi: 10.1007/s00262-018-2140-1. Epub 2018 Mar 2.
|
| 137 |
The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma.Leukemia. 2017 Apr;31(4):853-860. doi: 10.1038/leu.2016.296. Epub 2016 Oct 24.
|
| 138 |
Telomerase inhibitor MST-312 induces apoptosis of multiple myeloma cells and down-regulation of anti-apoptotic, proliferative and inflammatory genes.Life Sci. 2019 Jul 1;228:66-71. doi: 10.1016/j.lfs.2019.04.060. Epub 2019 Apr 25.
|
| 139 |
Kinase domain activation through gene rearrangement in multiple myeloma.Leukemia. 2018 Nov;32(11):2435-2444. doi: 10.1038/s41375-018-0108-y. Epub 2018 Mar 23.
|
| 140 |
Designing new generation of potent inhibitors against membrane-type matrix metalloproteinase-2: a computational effort against multiple myeloma.J Biomol Struct Dyn. 2020 Aug;38(13):3879-3891. doi: 10.1080/07391102.2019.1670736. Epub 2019 Oct 16.
|
| 141 |
Urinary NGAL for the diagnosis of the renal injury from multiple myeloma.Cancer Biomark. 2017;18(1):41-46. doi: 10.3233/CBM-160672.
|
| 142 |
The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma.Int J Cancer. 2020 Apr 1;146(7):1963-1978. doi: 10.1002/ijc.32615. Epub 2019 Aug 24.
|
| 143 |
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.J Clin Oncol. 2019 Aug 1;37(22):1946-1955. doi: 10.1200/JCO.19.00231. Epub 2019 Jun 12.
|
| 144 |
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma.J Hematol Oncol. 2019 Mar 21;12(1):32. doi: 10.1186/s13045-019-0714-9.
|
| 145 |
Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry.Int J Hematol. 2019 Apr;109(4):377-381. doi: 10.1007/s12185-019-02615-z. Epub 2019 Feb 18.
|
| 146 |
Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.Front Immunol. 2018 Oct 1;9:2264. doi: 10.3389/fimmu.2018.02264. eCollection 2018.
|
| 147 |
The synergistic effect of PFK15 with metformin exerts anti-myeloma activity via PFKFB3.Biochem Biophys Res Commun. 2019 Jul 23;515(2):332-338. doi: 10.1016/j.bbrc.2019.05.136. Epub 2019 May 29.
|
| 148 |
Identification of PIKfyve kinase as a target in multiple myeloma.Haematologica. 2020 Jun;105(6):1641-1649. doi: 10.3324/haematol.2019.222729. Epub 2019 Oct 3.
|
| 149 |
HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action.Cancers (Basel). 2019 Apr 4;11(4):475. doi: 10.3390/cancers11040475.
|
| 150 |
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.Leukemia. 2018 Apr;32(4):996-1002. doi: 10.1038/leu.2017.334. Epub 2017 Nov 21.
|
| 151 |
Spectrum and functional validation of PSMB5 mutations in multiple myeloma.Leukemia. 2019 Feb;33(2):447-456. doi: 10.1038/s41375-018-0216-8. Epub 2018 Jul 19.
|
| 152 |
Role of RACK1 on cell proliferation, adhesion, and bortezomib-induced apoptosis in multiple myeloma.Int J Biol Macromol. 2019 Jan;121:1077-1085. doi: 10.1016/j.ijbiomac.2018.10.034. Epub 2018 Oct 10.
|
| 153 |
Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma.Oncotarget. 2018 Apr 17;9(29):20563-20577. doi: 10.18632/oncotarget.25003. eCollection 2018 Apr 17.
|
| 154 |
RNF6 promotes myeloma cell proliferation and survival by inducing glucocorticoid receptor polyubiquitination.Acta Pharmacol Sin. 2020 Mar;41(3):394-403. doi: 10.1038/s41401-019-0309-6. Epub 2019 Oct 23.
|
| 155 |
Silencing RRM2 inhibits multiple myeloma bytargeting the Wnt/catenin signaling pathway.Mol Med Rep. 2019 Sep;20(3):2159-2166. doi: 10.3892/mmr.2019.10465. Epub 2019 Jul 3.
|
| 156 |
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.J Clin Oncol. 2019 May 10;37(14):1228-1263. doi: 10.1200/JCO.18.02096. Epub 2019 Apr 1.
|
| 157 |
Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma.Blood Cancer J. 2018 May 11;8(5):42. doi: 10.1038/s41408-018-0075-6.
|
| 158 |
Expression of TRPM8 in human reactive lymphoid tissues and mature B-cell neoplasms.Oncol Lett. 2018 Nov;16(5):5930-5938. doi: 10.3892/ol.2018.9386. Epub 2018 Sep 3.
|
| 159 |
Design, synthesis, and biological evaluation of novel ubiquitin-activating enzyme inhibitors.Bioorg Med Chem Lett. 2018 Sep 1;28(16):2723-2727. doi: 10.1016/j.bmcl.2018.03.004. Epub 2018 Mar 3.
|
| 160 |
High expression of UBE2T predicts poor prognosis and survival in multiple myeloma.Cancer Gene Ther. 2019 Nov;26(11-12):347-355. doi: 10.1038/s41417-018-0070-x. Epub 2019 Jan 9.
|
| 161 |
Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.Clin Cancer Res. 2017 Aug 1;23(15):4280-4289. doi: 10.1158/1078-0432.CCR-16-2692. Epub 2017 Mar 7.
|
| 162 |
Multidrug resistance gene expression and ABCB1 SNPs in plasma cell myeloma.Leuk Res. 2011 Nov;35(11):1457-63. doi: 10.1016/j.leukres.2011.05.033. Epub 2011 Jun 25.
|
| 163 |
A p110-specific inhibitor combined with bortezomib blocks drug resistance properties of EBV-related B cell origin cancer cells via regulation of NF-B.Int J Oncol. 2017 May;50(5):1711-1720. doi: 10.3892/ijo.2017.3923. Epub 2017 Mar 21.
|
| 164 |
Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients.Br J Haematol. 2018 Nov;183(3):375-384. doi: 10.1111/bjh.15521. Epub 2018 Aug 6.
|
| 165 |
The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma.Oncol Rep. 2019 Mar;41(3):1678-1690. doi: 10.3892/or.2019.6968. Epub 2019 Jan 11.
|
| 166 |
Detection of a rare BCR-ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS).Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16190-5. doi: 10.1073/pnas.1212759109. Epub 2012 Sep 17.
|
| 167 |
Utilizing BMP-2 muteins for treatment of multiple myeloma.PLoS One. 2017 May 10;12(5):e0174884. doi: 10.1371/journal.pone.0174884. eCollection 2017.
|
| 168 |
PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells.Exp Biol Med (Maywood). 2017 May;242(9):996-1004. doi: 10.1177/1535370216685008. Epub 2017 Jan 1.
|
| 169 |
Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.J Clin Invest. 2017 Jun 1;127(6):2066-2080. doi: 10.1172/JCI83936. Epub 2017 May 15.
|
| 170 |
Polycomb target genes are silenced in multiple myeloma.PLoS One. 2010 Jul 9;5(7):e11483. doi: 10.1371/journal.pone.0011483.
|
| 171 |
Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study.Leuk Lymphoma. 2019 Jul;60(7):1803-1811. doi: 10.1080/10428194.2018.1551536. Epub 2019 Jan 11.
|
| 172 |
Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway.Cancer Lett. 2019 Mar 1;444:45-59. doi: 10.1016/j.canlet.2018.12.014. Epub 2018 Dec 21.
|
| 173 |
Elevated serum angiogenin in multiple myeloma.Hematol J. 2003;4(6):454-5. doi: 10.1038/sj.thj.6200331.
|
| 174 |
Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma.Leuk Lymphoma. 2013 Jul;54(7):1473-8. doi: 10.3109/10428194.2012.745523. Epub 2012 Nov 26.
|
| 175 |
Screening and characterization of an Annexin A2 binding aptamer that inhibits the proliferation of myeloma cells.Biochimie. 2018 Aug;151:150-158. doi: 10.1016/j.biochi.2018.06.003. Epub 2018 Jun 15.
|
| 176 |
Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment.Blood. 2012 Feb 23;119(8):1888-96. doi: 10.1182/blood-2011-11-393348. Epub 2012 Jan 5.
|
| 177 |
EPA and DHA have selective toxicity for PBMCs from multiple myeloma patients in a partly caspase-dependent manner.Clin Nutr. 2020 Jul;39(7):2137-2143. doi: 10.1016/j.clnu.2019.08.031. Epub 2019 Sep 9.
|
| 178 |
Multiple myeloma-derived exosomes inhibit osteoblastic differentiation and improve IL-6 secretion of BMSCs from multiple myeloma.J Investig Med. 2020 Jan;68(1):45-51. doi: 10.1136/jim-2019-001010. Epub 2019 Nov 28.
|
| 179 |
Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis.J Hematol Oncol. 2019 Jan 8;12(1):2. doi: 10.1186/s13045-018-0689-y.
|
| 180 |
Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma.Leukemia. 2017 May;31(5):1123-1135. doi: 10.1038/leu.2016.325. Epub 2016 Nov 18.
|
| 181 |
Serum platelet factor 4 is a promising predictor in newly diagnosed patients with multiple myeloma treated with thalidomide and VAD regimens.Hematology. 2019 Dec;24(1):387-391. doi: 10.1080/16078454.2019.1592826.
|
| 182 |
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.Sci Rep. 2017 Jan 23;7:41071. doi: 10.1038/srep41071.
|
| 183 |
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.Haematologica. 2020 Mar;105(3):e116-e120. doi: 10.3324/haematol.2018.212308. Epub 2019 Jul 18.
|
| 184 |
Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.Haematologica. 2014 Aug;99(8):1365-72. doi: 10.3324/haematol.2013.087809. Epub 2014 May 9.
|
| 185 |
Interferon is a strong, STAT1-dependent direct inducer of BCL6 expression in multiple myeloma cells.Biochem Biophys Res Commun. 2018 Apr 6;498(3):502-508. doi: 10.1016/j.bbrc.2018.03.010. Epub 2018 Mar 3.
|
| 186 |
LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.Exp Cell Res. 2018 Sep 15;370(2):254-263. doi: 10.1016/j.yexcr.2018.06.026. Epub 2018 Jun 23.
|
| 187 |
Hyaluronan hydrogels delivering BMP-6 for local targeting of malignant plasma cells and osteogenic differentiation of mesenchymal stromal cells.Acta Biomater. 2019 Sep 15;96:258-270. doi: 10.1016/j.actbio.2019.07.018. Epub 2019 Jul 11.
|
| 188 |
Long Noncoding RNA H19 Promotes Tumorigenesis of Multiple Myeloma by Activating BRD4 Signaling by Targeting MicroRNA 152-3p.Mol Cell Biol. 2020 Jan 16;40(3):e00382-19. doi: 10.1128/MCB.00382-19. Print 2020 Jan 16.
|
| 189 |
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.Blood Cancer J. 2019 Feb 11;9(2):19. doi: 10.1038/s41408-019-0173-0.
|
| 190 |
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.Br J Haematol. 2003 Jan;120(1):44-52. doi: 10.1046/j.1365-2141.2003.03948.x.
|
| 191 |
Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications.Am J Hematol. 2019 May;94(S1):S28-S33. doi: 10.1002/ajh.25428. Epub 2019 Feb 25.
|
| 192 |
CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma.Cell Death Dis. 2019 Oct 14;10(10):781. doi: 10.1038/s41419-019-2012-4.
|
| 193 |
CCN1 stimulated the osteoblasts via PTEN/AKT/GSK3/cyclinD1 signal pathway in Myeloma Bone Disease.Cancer Med. 2020 Jan;9(2):737-744. doi: 10.1002/cam4.2608. Epub 2019 Nov 26.
|
| 194 |
Improved diagnostic segregation of mantle cell lymphoma by determination of cyclin D1/D3 expression ratio in formalin-fixed tissue.Diagn Mol Pathol. 2009 Sep;18(3):150-5. doi: 10.1097/PDM.0b013e31818935d2.
|
| 195 |
HIF-2 Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1.Cancer Res. 2017 Oct 15;77(20):5452-5463. doi: 10.1158/0008-5472.CAN-17-0115. Epub 2017 Aug 30.
|
| 196 |
Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients.Front Immunol. 2019 May 21;10:1079. doi: 10.3389/fimmu.2019.01079. eCollection 2019.
|
| 197 |
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200.J Immunother Cancer. 2019 Aug 23;7(1):227. doi: 10.1186/s40425-019-0710-1.
|
| 198 |
Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.Leuk Res. 2004 May;28(5):469-77. doi: 10.1016/j.leukres.2003.09.015.
|
| 199 |
The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression.Oncotarget. 2019 Sep 10;10(52):5480-5491. doi: 10.18632/oncotarget.27190. eCollection 2019 Sep 10.
|
| 200 |
Potential therapeutic targets in plasma cell disorders: A flow cytometry study.Cytometry B Clin Cytom. 2017 Mar;92(2):145-152. doi: 10.1002/cyto.b.21351. Epub 2016 Feb 3.
|
| 201 |
LncRNA NEAT1 sponges miR-214 to regulate M2 macrophage polarization by regulation of B7-H3 in multiple myeloma.Mol Immunol. 2020 Jan;117:20-28. doi: 10.1016/j.molimm.2019.10.026. Epub 2019 Nov 12.
|
| 202 |
CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.Acta Haematol. 2018;139(4):228-234. doi: 10.1159/000489483. Epub 2018 Jun 19.
|
| 203 |
CD40 stimulation induces vincristine resistance via AKT activation and MRP1 expression in a human multiple myeloma cell line.Immunol Lett. 2012 May 30;144(1-2):41-8. doi: 10.1016/j.imlet.2012.03.005. Epub 2012 Mar 14.
|
| 204 |
Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice.Leukemia. 2017 Oct;31(10):2114-2121. doi: 10.1038/leu.2017.69. Epub 2017 Feb 24.
|
| 205 |
JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.Br J Haematol. 2020 Jan;188(2):283-294. doi: 10.1111/bjh.16158. Epub 2019 Aug 18.
|
| 206 |
Blocking "don't eat me" signal of CD47-SIRP in hematological malignancies, an in-depth review.Blood Rev. 2018 Nov;32(6):480-489. doi: 10.1016/j.blre.2018.04.005. Epub 2018 Apr 14.
|
| 207 |
Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates.Nat Commun. 2017 Oct 24;8(1):1112. doi: 10.1038/s41467-017-01257-1.
|
| 208 |
Bone marrow eosinophils in plasma cell disorders.Exp Hematol. 2018 Oct;66:27-31.e5. doi: 10.1016/j.exphem.2018.06.288. Epub 2018 Jul 5.
|
| 209 |
Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells.Blood. 1999 Mar 1;93(5):1482-6.
|
| 210 |
Identification of the APC/C co-factor FZR1 as a novel therapeutic target for multiple myeloma.Oncotarget. 2016 Oct 25;7(43):70481-70493. doi: 10.18632/oncotarget.12026.
|
| 211 |
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.Blood. 2014 Jan 30;123(5):706-16. doi: 10.1182/blood-2013-05-500033. Epub 2013 Dec 6.
|
| 212 |
Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.Int J Oncol. 2004 Sep;25(3):579-95.
|
| 213 |
Using Prognosis-Related Gene Expression Signature and Connectivity Map for Personalized Drug Repositioning in Multiple Myeloma.Med Sci Monit. 2019 May 2;25:3247-3255. doi: 10.12659/MSM.913970.
|
| 214 |
Antitumoral effect of arsenic compound, sodium metaarsenite (KML001), on multiple myeloma cells.Int J Oncol. 2017 Dec;51(6):1739-1746. doi: 10.3892/ijo.2017.4161. Epub 2017 Oct 16.
|
| 215 |
Targeting glutaminase1 and synergizing with clinical drugs achieved more promising antitumor activity on multiple myeloma.Oncotarget. 2019 Oct 15;10(57):5993-6005. doi: 10.18632/oncotarget.27243. eCollection 2019 Oct 15.
|
| 216 |
MicroRNA-26a inhibits multiple myeloma cell growth by suppressing cyclin-dependent kinase 6 expression.Kaohsiung J Med Sci. 2019 May;35(5):277-283. doi: 10.1002/kjm2.12057. Epub 2019 Mar 21.
|
| 217 |
Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.Blood. 2019 Apr 4;133(14):1572-1584. doi: 10.1182/blood-2018-06-859686. Epub 2019 Feb 8.
|
| 218 |
IL-6-induced activation of MYC is responsible for the down-regulation of CD33 expression in CD33+ myeloma cells.Int J Hematol. 2009 Apr;89(3):310-318. doi: 10.1007/s12185-009-0256-y. Epub 2009 Mar 4.
|
| 219 |
Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia invivo in a mouse xenogtraft model.Cancer Lett. 2017 Mar 28;389:70-77. doi: 10.1016/j.canlet.2016.12.010. Epub 2016 Dec 18.
|
| 220 |
Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1.J Immunol. 2014 Jul 15;193(2):950-60. doi: 10.4049/jimmunol.1400271. Epub 2014 Jun 9.
|
| 221 |
The IKK inhibitor Bay 11-7082 induces cell death independent from inhibition of activation of NFB transcription factors.PLoS One. 2013;8(3):e59292. doi: 10.1371/journal.pone.0059292. Epub 2013 Mar 20.
|
| 222 |
MYD88 L265P in Waldenstrm macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.Blood. 2013 Mar 14;121(11):2051-8. doi: 10.1182/blood-2012-09-454355. Epub 2013 Jan 15.
|
| 223 |
The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential.MAbs. 2013 Jul-Aug;5(4):587-94. doi: 10.4161/mabs.25077. Epub 2013 May 29.
|
| 224 |
A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity.Mol Cancer Ther. 2019 Oct;18(10):1822-1831. doi: 10.1158/1535-7163.MCT-19-0115. Epub 2019 Aug 8.
|
| 225 |
Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro.Cancer Immunol Immunother. 2006 Apr;55(4):375-85. doi: 10.1007/s00262-005-0011-z. Epub 2005 Jul 2.
|
| 226 |
CSNK11 mediates malignant plasma cell survival.Leukemia. 2015 Feb;29(2):474-82. doi: 10.1038/leu.2014.202. Epub 2014 Jun 25.
|
| 227 |
Decreasing New York esophageal squamous cell carcinoma 1 expression inhibits multiple myeloma growth and osteolytic lesions.J Cell Physiol. 2020 Mar;235(3):2183-2194. doi: 10.1002/jcp.29128. Epub 2019 Sep 5.
|
| 228 |
Expression of testicular genes in haematological malignancies.Br J Cancer. 1999 Dec;81(7):1162-4. doi: 10.1038/sj.bjc.6690824.
|
| 229 |
Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells.Br J Haematol. 2005 Apr;129(2):248-56. doi: 10.1111/j.1365-2141.2005.05443.x.
|
| 230 |
Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells.J Immunother Cancer. 2019 Nov 7;7(1):290. doi: 10.1186/s40425-019-0751-5.
|
| 231 |
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.Clin Cancer Res. 2020 Jan 15;26(2):344-353. doi: 10.1158/1078-0432.CCR-19-0647. Epub 2019 Oct 31.
|
| 232 |
NCOA1 is a novel susceptibility gene for multiple myeloma in the Chinese population: A case-control study.PLoS One. 2017 Mar 6;12(3):e0173298. doi: 10.1371/journal.pone.0173298. eCollection 2017.
|
| 233 |
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.Blood. 2014 May 22;123(21):3269-76. doi: 10.1182/blood-2013-08-521914. Epub 2014 Apr 8.
|
| 234 |
SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis.Cancer Lett. 2009 Jun 8;278(1):41-8. doi: 10.1016/j.canlet.2008.12.022. Epub 2009 Jan 25.
|
| 235 |
DEK protein level is a biomarker of CD138positive normal and malignant plasma cells.PLoS One. 2017 May 30;12(5):e0178025. doi: 10.1371/journal.pone.0178025. eCollection 2017.
|
| 236 |
Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.PLoS One. 2013 Apr 30;8(4):e62752. doi: 10.1371/journal.pone.0062752. Print 2013.
|
| 237 |
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.Nat Genet. 2013 May;45(5):522-525. doi: 10.1038/ng.2583. Epub 2013 Mar 17.
|
| 238 |
Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. Cancer Res. 2007 Jun 1;67(11):5328-36. doi: 10.1158/0008-5472.CAN-06-4265.
|
| 239 |
CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma.Blood Cancer J. 2018 Oct 22;8(11):99. doi: 10.1038/s41408-018-0127-y.
|
| 240 |
No preferential use of the VH(V) family in human multiple myeloma.Br J Haematol. 1989 Dec;73(4):486-90. doi: 10.1111/j.1365-2141.1989.tb00285.x.
|
| 241 |
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.Eur J Haematol. 2010 Jan 1;84(1):47-51. doi: 10.1111/j.1600-0609.2009.01344.x. Epub 2009 Sep 8.
|
| 242 |
Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS One. 2013 Jul 31;8(7):e70430.
|
| 243 |
Epha3 acts as proangiogenic factor in multiple myeloma.Oncotarget. 2017 May 23;8(21):34298-34309. doi: 10.18632/oncotarget.16100.
|
| 244 |
Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.Cancer Sci. 2019 Jan;110(1):194-208. doi: 10.1111/cas.13840. Epub 2018 Nov 16.
|
| 245 |
Indirect Tumor Inhibitory Effects of MicroRNA-124 through Targeting EZH2 in The Multiple Myeloma Cell Line.Cell J. 2020 Apr;22(1):23-29. doi: 10.22074/cellj.2020.6492. Epub 2019 Sep 8.
|
| 246 |
Interactions of human mesangial cells with IgA and IgA-containing immune complexes.Kidney Int. 2002 Aug;62(2):465-75. doi: 10.1046/j.1523-1755.2002.00477.x.
|
| 247 |
Clinicopathologic analysis of the impact of CD23 expression in plasma cell myeloma with t(11;14)(q13;q32).Ann Diagn Pathol. 2011 Dec;15(6):385-8. doi: 10.1016/j.anndiagpath.2011.04.004. Epub 2011 Jul 2.
|
| 248 |
Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw.Front Biosci (Elite Ed). 2011 Jan 1;3(1):364-70. doi: 10.2741/e251.
|
| 249 |
Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia.Oncotarget. 2017 Mar 21;8(12):19427-19442. doi: 10.18632/oncotarget.14294.
|
| 250 |
Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.Eur J Haematol. 2017 Oct;99(4):300-305. doi: 10.1111/ejh.12917. Epub 2017 Jul 20.
|
| 251 |
Glucosylceramidases and malignancies in mammals.Biochimie. 2016 Jun;125:267-80. doi: 10.1016/j.biochi.2015.11.009. Epub 2015 Nov 12.
|
| 252 |
Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials.Leukemia. 2018 Apr;32(4):971-978. doi: 10.1038/leu.2017.320. Epub 2017 Nov 3.
|
| 253 |
Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis.Blood. 2016 Jun 16;127(24):3035-9. doi: 10.1182/blood-2015-10-673095. Epub 2016 Apr 11.
|
| 254 |
Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation.Leuk Res. 2006 May;30(5):529-35. doi: 10.1016/j.leukres.2005.09.004. Epub 2005 Oct 24.
|
| 255 |
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019 Mar 27;11(485):eaau7746.
|
| 256 |
Metabotropic glutamate receptor 3 is involved in B-cell-related tumor apoptosis.Int J Oncol. 2016 Oct;49(4):1469-78. doi: 10.3892/ijo.2016.3623. Epub 2016 Jul 15.
|
| 257 |
Analysis of Global Gene Expression Profiles.Methods Mol Biol. 2018;1792:157-166. doi: 10.1007/978-1-4939-7865-6_11.
|
| 258 |
Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells.J Biol Chem. 2004 May 14;279(20):21658-65. doi: 10.1074/jbc.M305783200. Epub 2004 Mar 9.
|
| 259 |
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling.Leukemia. 2020 Jan;34(1):196-209. doi: 10.1038/s41375-019-0493-x. Epub 2019 May 29.
|
| 260 |
Long noncoding RNA TUG1 promotes proliferation and inhibits apoptosis in multiple myeloma by inhibiting miR-29b-3p.Biosci Rep. 2019 Mar 22;39(3):BSR20182489. doi: 10.1042/BSR20182489. Print 2019 Mar 29.
|
| 261 |
A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression.Cancer Res. 2020 Feb 1;80(3):536-548. doi: 10.1158/0008-5472.CAN-18-3987. Epub 2019 Nov 15.
|
| 262 |
Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator.Blood. 2004 Oct 1;104(7):2172-5. doi: 10.1182/blood-2003-12-4386. Epub 2004 Jun 1.
|
| 263 |
Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.Blood Adv. 2019 Jul 9;3(13):2022-2034. doi: 10.1182/bloodadvances.2019000194.
|
| 264 |
Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism.Acta Biochim Biophys Sin (Shanghai). 2014 Jul;46(7):597-604. doi: 10.1093/abbs/gmu041. Epub 2014 May 21.
|
| 265 |
Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma.PLoS One. 2012;7(2):e30359. doi: 10.1371/journal.pone.0030359. Epub 2012 Feb 17.
|
| 266 |
Heparanase promotes myeloma stemness and in vivo tumorigenesis.Matrix Biol. 2020 Jun;88:53-68. doi: 10.1016/j.matbio.2019.11.004. Epub 2019 Dec 5.
|
| 267 |
Targeting HSF1: A Prime Integrator of Proteotoxic Stress Response in Myeloma.Clin Cancer Res. 2018 May 15;24(10):2237-2238. doi: 10.1158/1078-0432.CCR-18-0030. Epub 2018 Feb 9.
|
| 268 |
Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells.Clin Exp Med. 2020 Feb;20(1):63-71. doi: 10.1007/s10238-019-00587-2. Epub 2019 Oct 24.
|
| 269 |
15d-PGJ(2) as an endoplasmic reticulum stress manipulator in multiple myeloma in vitro and in vivo.Exp Mol Pathol. 2017 Jun;102(3):434-445. doi: 10.1016/j.yexmp.2017.05.003. Epub 2017 May 12.
|
| 270 |
GRP78 modulates cell adhesion markers in prostate Cancer and multiple myeloma cell lines.BMC Cancer. 2018 Dec 18;18(1):1263. doi: 10.1186/s12885-018-5178-8.
|
| 271 |
The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma.Haematologica. 2013 Jul;98(7):1132-41. doi: 10.3324/haematol.2012.066175. Epub 2012 Oct 12.
|
| 272 |
Bortezomib promotes apoptosis of multiple myeloma cells by regulating HSP27.Mol Med Rep. 2019 Sep;20(3):2410-2418. doi: 10.3892/mmr.2019.10467. Epub 2019 Jul 3.
|
| 273 |
Identification of ID-1 as a potential target gene of MMSET in multiple myeloma.Br J Haematol. 2005 Sep;130(5):700-8. doi: 10.1111/j.1365-2141.2005.05664.x.
|
| 274 |
Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era: A Meta-analysis.Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):558-568. doi: 10.1016/j.clml.2018.06.004. Epub 2018 Jun 8.
|
| 275 |
Ribosomal protein metallopanstimulin-1 impairs multiple myeloma CAG cells growth and inhibits fibroblast growth factor receptor 3.Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):490-7. doi: 10.1016/j.clml.2011.06.015. Epub 2011 Sep 1.
|
| 276 |
All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma.Haematologica. 1997 May-Jun;82(3):354-6.
|
| 277 |
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.Leukemia. 2019 Aug;33(8):2006-2021. doi: 10.1038/s41375-019-0403-2. Epub 2019 Feb 13.
|
| 278 |
Expression of interleukin-11 receptor in CD38-positive cells from patients with multiple myeloma.Leuk Lymphoma. 2004 Nov;45(11):2315-9. doi: 10.1080/10428190412331283161.
|
| 279 |
Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.Blood. 2008 Aug 1;112(3):750-9. doi: 10.1182/blood-2008-02-139378. Epub 2008 May 12.
|
| 280 |
Drug-Induced Senescent Multiple Myeloma Cells Elicit NK Cell Proliferation by Direct or Exosome-Mediated IL15 Trans-Presentation.Cancer Immunol Res. 2018 Jul;6(7):860-869. doi: 10.1158/2326-6066.CIR-17-0604. Epub 2018 Apr 24.
|
| 281 |
Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation.Oncotarget. 2017 Jul 25;8(30):49253-49263. doi: 10.18632/oncotarget.17534.
|
| 282 |
Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms.Leukemia. 2010 Jun;24(6):1171-8. doi: 10.1038/leu.2010.50. Epub 2010 Apr 15.
|
| 283 |
IL21R expressing CD14(+)CD16(+) monocytes expand in multiple myeloma patients leading to increased osteoclasts.Haematologica. 2017 Apr;102(4):773-784. doi: 10.3324/haematol.2016.153841. Epub 2017 Jan 5.
|
| 284 |
Multiple myeloma cell-derived IL-32 increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression.Cancer Lett. 2019 Apr 1;446:38-48. doi: 10.1016/j.canlet.2019.01.012. Epub 2019 Jan 18.
|
| 285 |
Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer.Mol Med. 2012 Feb 10;18(1):65-75. doi: 10.2119/molmed.2011.00178.
|
| 286 |
Multiple myeloma BM-MSCs increase the tumorigenicity of MM cells via transfer of VLA4-enriched microvesicles.Carcinogenesis. 2020 Mar 13;41(1):100-110. doi: 10.1093/carcin/bgz169.
|
| 287 |
Unfolded protein response inducers tunicamycin and dithiothreitol promote myeloma cell differentiation mediated by XBP-1.Clin Exp Med. 2015 Feb;15(1):85-96. doi: 10.1007/s10238-013-0269-y. Epub 2013 Dec 20.
|
| 288 |
Highly Expressed Integrin-8 Induces Epithelial to Mesenchymal Transition-Like Features in Multiple Myeloma with Early Relapse. Mol Cells. 2016 Dec;39(12):898-908.
|
| 289 |
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.Oncogene. 2001 Jul 27;20(33):4519-27. doi: 10.1038/sj.onc.1204623.
|
| 290 |
Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma.Cancers (Basel). 2019 Dec 15;11(12):2024. doi: 10.3390/cancers11122024.
|
| 291 |
Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance.Haematologica. 2020 Jul;105(7):1925-1936. doi: 10.3324/haematol.2019.221077. Epub 2019 Oct 3.
|
| 292 |
LMP1 expression in bone marrow trephines of patients with multiple myeloma confers a survival advantage.Leuk Lymphoma. 2019 Aug;60(8):1991-2001. doi: 10.1080/10428194.2018.1563697. Epub 2019 Mar 26.
|
| 293 |
Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A.Front Immunol. 2018 Dec 4;9:2848. doi: 10.3389/fimmu.2018.02848. eCollection 2018.
|
| 294 |
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.Cancer Immunol Res. 2019 Jan;7(1):100-112. doi: 10.1158/2326-6066.CIR-18-0307. Epub 2018 Nov 5.
|
| 295 |
Genetic and transcriptional landscape of plasma cells in POEMS syndrome.Leukemia. 2019 Jul;33(7):1723-1735. doi: 10.1038/s41375-018-0348-x. Epub 2019 Jan 11.
|
| 296 |
Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation.Onco Targets Ther. 2017 Apr 4;10:1977-1982. doi: 10.2147/OTT.S124321. eCollection 2017.
|
| 297 |
Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins.Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):376-381. doi: 10.1073/pnas.1618650114. Epub 2016 Dec 27.
|
| 298 |
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.Blood. 2012 Nov 8;120(19):3958-67. doi: 10.1182/blood-2012-01-401794. Epub 2012 Sep 14.
|
| 299 |
PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.Mol Cancer Ther. 2013 Nov;12(11):2331-41. doi: 10.1158/1535-7163.MCT-12-1166. Epub 2013 Sep 12.
|
| 300 |
The role of surface molecule CD229 in Multiple Myeloma.Clin Immunol. 2019 Jul;204:69-73. doi: 10.1016/j.clim.2018.10.006. Epub 2018 Oct 13.
|
| 301 |
The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells.Eur J Immunol. 2000 Mar;30(3):803-9. doi: 10.1002/1521-4141(200003)30:3<803::AID-IMMU803>3.0.CO;2-P.
|
| 302 |
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.Haematologica. 2019 Oct;104(10):2061-2074. doi: 10.3324/haematol.2018.211110. Epub 2019 Mar 7.
|
| 303 |
TPL2 kinase regulates the inflammatory milieu of the myeloma niche.Blood. 2014 May 22;123(21):3305-15. doi: 10.1182/blood-2014-02-554071. Epub 2014 Apr 10.
|
| 304 |
Multifunctional role of Erk5 in multiple myeloma.Blood. 2005 Jun 1;105(11):4492-9. doi: 10.1182/blood-2004-08-2985. Epub 2005 Feb 3.
|
| 305 |
Knockdown of long non-coding RNA PCAT-1 inhibits myeloma cell growth and drug resistance via p38 and JNK MAPK pathways.J Cancer. 2019 Oct 20;10(26):6502-6510. doi: 10.7150/jca.35098. eCollection 2019.
|
| 306 |
Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma.Oncogene. 2013 Sep 5;32(36):4231-42. doi: 10.1038/onc.2012.448. Epub 2012 Oct 8.
|
| 307 |
New insights in myeloma-induced osteolysis.Leuk Lymphoma. 2003 Sep;44(9):1463-7. doi: 10.3109/10428190309178765.
|
| 308 |
Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.Leukemia. 2015 Mar;29(3):715-26. doi: 10.1038/leu.2014.255. Epub 2014 Sep 2.
|
| 309 |
The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT).Front Immunol. 2018 Sep 20;9:2153. doi: 10.3389/fimmu.2018.02153. eCollection 2018.
|
| 310 |
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.Invest New Drugs. 2020 Jun;38(3):831-843. doi: 10.1007/s10637-019-00840-1. Epub 2019 Jul 29.
|
| 311 |
Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry.Arch Pathol Lab Med. 2017 Sep;141(9):1236-1246. doi: 10.5858/arpa.2016-0521-RA. Epub 2017 Jun 13.
|
| 312 |
Expression and induction of collagenases (MMP-8 and -13) in plasma cells associated with bone-destructive lesions.J Pathol. 2001 Jun;194(2):217-24. doi: 10.1002/path.854.
|
| 313 |
In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma.Front Immunol. 2019 Aug 2;10:1792. doi: 10.3389/fimmu.2019.01792. eCollection 2019.
|
| 314 |
Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cells.Int J Hematol. 2015 Nov;102(5):569-78. doi: 10.1007/s12185-015-1859-0. Epub 2015 Sep 4.
|
| 315 |
Simultaneous Presentation of Waldenstrm's Macroglobulinemia and MYD88 Gene Mutation with Multiple Myeloma.Cureus. 2019 Jan 3;11(1):e3822. doi: 10.7759/cureus.3822.
|
| 316 |
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.Blood. 2019 Jan 10;133(2):156-167. doi: 10.1182/blood-2018-05-850826. Epub 2018 Nov 19.
|
| 317 |
A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):29-34. doi: 10.1016/j.clml.2018.08.018. Epub 2018 Sep 5.
|
| 318 |
Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy.Immunology. 2013 Jul;139(3):338-41. doi: 10.1111/imm.12082.
|
| 319 |
Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor B pathways.Cancer Sci. 2019 Dec;110(12):3802-3810. doi: 10.1111/cas.14209. Epub 2019 Oct 23.
|
| 320 |
Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma.BMC Cancer. 2018 Nov 21;18(1):1152. doi: 10.1186/s12885-018-5015-0.
|
| 321 |
The effect of marrow stromal cells on TRAF6 expression levels in myeloma cells.Oncol Lett. 2017 Aug;14(2):1464-1470. doi: 10.3892/ol.2017.6322. Epub 2017 Jun 6.
|
| 322 |
Haplotypic structure across the I kappa B alpha gene (NFKBIA) and association with multiple myeloma.Cancer Lett. 2007 Feb 8;246(1-2):92-9. doi: 10.1016/j.canlet.2006.02.001. Epub 2006 Mar 15.
|
| 323 |
Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.Cancer Res. 2016 Mar 1;76(5):1225-36. doi: 10.1158/0008-5472.CAN-15-2934. Epub 2016 Feb 12.
|
| 324 |
Long-term reduction of amplified ornithine decarboxylase sequences in human myeloma cells.Biochem J. 1995 Aug 15;310 ( Pt 1)(Pt 1):299-303. doi: 10.1042/bj3100299.
|
| 325 |
Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma.Sci Rep. 2017 Dec 21;7(1):17993. doi: 10.1038/s41598-017-18446-z.
|
| 326 |
The clinical characteristics and prognosis of IGH deletion in multiple myeloma.Leuk Res. 2015 May;39(5):515-9. doi: 10.1016/j.leukres.2015.02.010. Epub 2015 Mar 18.
|
| 327 |
Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells.Leuk Res. 2012 Oct;36(10):1315-22. doi: 10.1016/j.leukres.2012.07.003. Epub 2012 Jul 19.
|
| 328 |
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma.Leukemia. 2020 Jan;34(1):234-244. doi: 10.1038/s41375-019-0542-5. Epub 2019 Aug 19.
|
| 329 |
Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITG7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.Appl Immunohistochem Mol Morphol. 2015 May-Jun;23(5):327-33. doi: 10.1097/PAI.0000000000000089.
|
| 330 |
PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells.Blood Cells Mol Dis. 2001 Sep-Oct;27(5):825-9. doi: 10.1006/bcmd.2001.0452.
|
| 331 |
Downregulation of CKS1B restrains the proliferation, migration, invasion and angiogenesis of retinoblastoma cells through the MEK/ERK signaling pathway.Int J Mol Med. 2019 Jul;44(1):103-114. doi: 10.3892/ijmm.2019.4183. Epub 2019 May 8.
|
| 332 |
PDCD1 and PDCD1LG1 polymorphisms affect the susceptibility to multiple myeloma.Clin Exp Med. 2020 Feb;20(1):51-62. doi: 10.1007/s10238-019-00585-4. Epub 2019 Oct 16.
|
| 333 |
PDK1 inhibitor GSK2334470 synergizes with proteasome inhibitor MG?32 in multiple myeloma cells by inhibiting full AKT activity and increasing nuclear accumulation of the PTEN protein.Oncol Rep. 2018 Jun;39(6):2951-2959. doi: 10.3892/or.2018.6369. Epub 2018 Apr 12.
|
| 334 |
Chromosomal instability and acquired drug resistance in multiple myeloma.Oncotarget. 2017 Sep 11;8(44):78234-78244. doi: 10.18632/oncotarget.20829. eCollection 2017 Sep 29.
|
| 335 |
Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.Am J Pathol. 2004 Jul;165(1):71-81. doi: 10.1016/S0002-9440(10)63276-2.
|
| 336 |
Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.Cancer Lett. 2019 Jan;440-441:1-10. doi: 10.1016/j.canlet.2018.10.003. Epub 2018 Oct 9.
|
| 337 |
Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.Br J Haematol. 2018 Jan;180(2):246-258. doi: 10.1111/bjh.15033.
|
| 338 |
PRAME Gene Copy Number Variation Is Related to Its Expression in Multiple Myeloma.DNA Cell Biol. 2017 Dec;36(12):1099-1107. doi: 10.1089/dna.2017.3951. Epub 2017 Sep 27.
|
| 339 |
Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma.Redox Biol. 2020 Jan;28:101310. doi: 10.1016/j.redox.2019.101310. Epub 2019 Aug 28.
|
| 340 |
Construction of a recombinant lentivirus-mediated shRNA expression vector targeting the human PSMD10 gene and validation of RNAi efficiency in RPMI?226 multiple myeloma cells.Oncol Rep. 2017 Aug;38(2):809-818. doi: 10.3892/or.2017.5770. Epub 2017 Jun 30.
|
| 341 |
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.Eur J Med Chem. 2019 Feb 15;164:59-76. doi: 10.1016/j.ejmech.2018.12.029. Epub 2018 Dec 15.
|
| 342 |
Effects of BENC-511, a novel PI3K inhibitor, on the proliferation and apoptosis of A549 human lung adenocarcinoma cells.Biosci Trends. 2019;13(1):40-48. doi: 10.5582/bst.2019.01006.
|
| 343 |
IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.Cancer Res. 2019 Sep 15;79(18):4679-4688. doi: 10.1158/0008-5472.CAN-19-0343. Epub 2019 Jul 23.
|
| 344 |
Clinical effects of CD45 on the prognosis of extramedullary myeloma relapse.J Clin Pharm Ther. 2020 Feb;45(1):144-151. doi: 10.1111/jcpt.13045. Epub 2019 Sep 18.
|
| 345 |
Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment.Exp Hematol. 2011 May;39(5):546-557.e8. doi: 10.1016/j.exphem.2011.02.002. Epub 2011 Mar 3.
|
| 346 |
Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.Leuk Lymphoma. 2013 Apr;54(4):843-50. doi: 10.3109/10428194.2012.731599. Epub 2012 Oct 9.
|
| 347 |
Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma.Clin Cancer Res. 2013 Nov 15;19(22):6242-51. doi: 10.1158/1078-0432.CCR-13-2083. Epub 2013 Sep 27.
|
| 348 |
Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression.Mol Cancer Res. 2018 Jul;16(7):1138-1148. doi: 10.1158/1541-7786.MCR-17-0606. Epub 2018 Mar 28.
|
| 349 |
Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma.J Immunol. 2018 Apr 15;200(8):2581-2591. doi: 10.4049/jimmunol.1701622. Epub 2018 Mar 12.
|
| 350 |
Sphingosine-1-phosphate activates chemokine-promoted myeloma cell adhesion and migration involving 41 integrin function.J Pathol. 2013 Jan;229(1):36-48. doi: 10.1002/path.4066.
|
| 351 |
Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.Hematol Oncol. 2019 Dec;37(5):586-594. doi: 10.1002/hon.2688. Epub 2019 Nov 23.
|
| 352 |
Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination.Leukemia. 2020 Jan;34(1):245-256. doi: 10.1038/s41375-019-0519-4. Epub 2019 Aug 22.
|
| 353 |
Relapsing bullous amyloidosis of the oral mucosa and acquired cutis laxa in a patient with multiple myeloma: a rare triple association.Clin Exp Dermatol. 2017 Jun;42(4):410-412. doi: 10.1111/ced.13084. Epub 2017 Mar 1.
|
| 354 |
EEN regulates the proliferation and survival of multiple myeloma cells by potentiating IGF-1 secretion.Biochem Biophys Res Commun. 2014 May 2;447(2):271-7. doi: 10.1016/j.bbrc.2014.03.127. Epub 2014 Apr 2.
|
| 355 |
Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma.Leukemia. 2017 Mar;31(3):645-653. doi: 10.1038/leu.2016.258. Epub 2016 Sep 28.
|
| 356 |
Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.Leukemia. 2020 Jan;34(1):180-195. doi: 10.1038/s41375-019-0525-6. Epub 2019 Jul 29.
|
| 357 |
Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation.Oncotarget. 2015 Oct 20;6(32):33568-86. doi: 10.18632/oncotarget.5598.
|
| 358 |
Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy.Blood. 2012 May 17;119(20):4686-97. doi: 10.1182/blood-2011-09-377846. Epub 2012 Mar 27.
|
| 359 |
Development of GLUT4-selective antagonists for multiple myeloma therapy.Eur J Med Chem. 2017 Oct 20;139:573-586. doi: 10.1016/j.ejmech.2017.08.029. Epub 2017 Aug 14.
|
| 360 |
Glucose transporters in cancer metabolism.Curr Opin Oncol. 2012 Nov;24(6):650-4. doi: 10.1097/CCO.0b013e328356da72.
|
| 361 |
A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis.Oncotarget. 2016 Sep 13;7(37):59029-59048. doi: 10.18632/oncotarget.10665.
|
| 362 |
Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.Biochem Pharmacol. 2009 Nov 1;78(9):1139-47. doi: 10.1016/j.bcp.2009.06.023. Epub 2009 Jun 23.
|
| 363 |
Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake.Acta Haematol. 2000;103(3):144-51. doi: 10.1159/000041037.
|
| 364 |
A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients.Anticancer Res. 2019 Jan;39(1):67-72. doi: 10.21873/anticanres.13080.
|
| 365 |
Integrated molecular profiling of SOD2 expression in multiple myeloma.Blood. 2007 May 1;109(9):3953-62. doi: 10.1182/blood-2006-07-035162. Epub 2006 Dec 27.
|
| 366 |
Increased Osteoblastic Activity Suppressed Proliferation of Multiple Myeloma Plasma Cells.Spine (Phila Pa 1976). 2019 Apr 1;44(7):E384-E392. doi: 10.1097/BRS.0000000000002873.
|
| 367 |
Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.Cancer Res. 2008 Jan 1;68(1):44-54. doi: 10.1158/0008-5472.CAN-07-2531.
|
| 368 |
The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.Cancer Med. 2018 Jul;7(7):3257-3268. doi: 10.1002/cam4.1543. Epub 2018 May 15.
|
| 369 |
Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.J Biol Chem. 2014 Feb 28;289(9):5499-509. doi: 10.1074/jbc.M113.532143. Epub 2014 Jan 8.
|
| 370 |
STEAP1 is overexpressed in cancers: a promising therapeutic target.Biochem Biophys Res Commun. 2012 Dec 14;429(3-4):148-55. doi: 10.1016/j.bbrc.2012.10.123. Epub 2012 Nov 6.
|
| 371 |
CD4?T cells in chronic autoantigenic stimulation in MGUS, multiple myeloma and Waldenstrm's macroglobulinemia.Int J Cancer. 2015 Sep 1;137(5):1076-84. doi: 10.1002/ijc.29478. Epub 2015 Feb 26.
|
| 372 |
Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma.Br J Haematol. 2004 Jul;126(1):72-6. doi: 10.1111/j.1365-2141.2004.04996.x.
|
| 373 |
DNA hypermethylation and partial gene silencing of human thymine- DNA glycosylase in multiple myeloma cell lines.Epigenetics. 2006 Jul-Sep;1(3):138-45. doi: 10.4161/epi.1.3.2938. Epub 2006 May 25.
|
| 374 |
Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma.Mol Med. 2010 Nov-Dec;16(11-12):471-8. doi: 10.2119/molmed.2010.00057. Epub 2010 Jul 14.
|
| 375 |
Thymosin 4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.Haematologica. 2010 Jan;95(1):163-7. doi: 10.3324/haematol.2009.006411. Epub 2009 Oct 14.
|
| 376 |
NF-B-dependent RANKL expression in a mouse model of immature T-cell leukemia.Biochem Biophys Res Commun. 2019 Mar 5;510(2):272-277. doi: 10.1016/j.bbrc.2019.01.089. Epub 2019 Jan 30.
|
| 377 |
A role of both NF-B pathways in expression and transcription regulation of BAFF-R gene in multiple myeloma cells.Mol Cell Biochem. 2011 Nov;357(1-2):21-30. doi: 10.1007/s11010-011-0871-9. Epub 2011 May 24.
|
| 378 |
Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.PLoS One. 2015 May 14;10(5):e0127334. doi: 10.1371/journal.pone.0127334. eCollection 2015.
|
| 379 |
High expression of TRAIL by osteoblastic differentiated dental pulp stem cells affects myeloma cell viability.Oncol Rep. 2018 Apr;39(4):2031-2039. doi: 10.3892/or.2018.6272. Epub 2018 Feb 15.
|
| 380 |
Role of the RANK/RANKL Pathway in Multiple Myeloma.Clin Cancer Res. 2019 Jan 1;25(1):12-20. doi: 10.1158/1078-0432.CCR-18-1537. Epub 2018 Aug 9.
|
| 381 |
Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance.Oncol Lett. 2017 Sep;14(3):2657-2662. doi: 10.3892/ol.2017.6528. Epub 2017 Jul 7.
|
| 382 |
Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells.Oncotarget. 2017 Jun 20;8(25):41091-41101. doi: 10.18632/oncotarget.17056.
|
| 383 |
Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.Semin Hematol. 1997 Oct;34(4 Suppl 5):48-62.
|
| 384 |
Expression profile of shelterin components in plasma cell disorders. Clinical significance of POT1 overexpression.Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):134-9. doi: 10.1016/j.bcmd.2013.10.002. Epub 2013 Nov 14.
|
| 385 |
TRAF6 Silencing Attenuates Multiple Myeloma Cell Adhesion to Bone Marrow Stromal Cells.Int J Mol Sci. 2019 Feb 6;20(3):702. doi: 10.3390/ijms20030702.
|
| 386 |
MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma.Sci Rep. 2017 Jun 2;7(1):2685. doi: 10.1038/s41598-017-02713-0.
|
| 387 |
TRPV2-induced Ca(2+)-calcineurin-NFAT signaling regulates differentiation of osteoclast in multiple myeloma.Cell Commun Signal. 2018 Oct 16;16(1):68. doi: 10.1186/s12964-018-0280-8.
|
| 388 |
Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo.Exp Cell Res. 2015 Mar 1;332(1):24-38. doi: 10.1016/j.yexcr.2015.01.006. Epub 2015 Jan 28.
|
| 389 |
Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.J Hematol Oncol. 2018 Feb 27;11(1):29. doi: 10.1186/s13045-018-0575-7.
|
| 390 |
Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.Leukemia. 2015 Mar;29(3):696-704. doi: 10.1038/leu.2014.236. Epub 2014 Aug 8.
|
| 391 |
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.Cancer Res. 2005 Sep 15;65(18):8350-8. doi: 10.1158/0008-5472.CAN-05-0163.
|
| 392 |
miR-125a suppresses malignancy of multiple myeloma by reducing the deubiquitinase USP5.J Cell Biochem. 2020 Jan;121(1):642-650. doi: 10.1002/jcb.29309. Epub 2019 Aug 26.
|
| 393 |
Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.J Clin Invest. 2018 Jul 2;128(7):2877-2893. doi: 10.1172/JCI98765. Epub 2018 Jun 4.
|
| 394 |
Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1666-1676. doi: 10.1016/j.bbadis.2019.04.003. Epub 2019 Apr 4.
|
| 395 |
Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer.PLoS One. 2011 Jan 31;6(1):e14635. doi: 10.1371/journal.pone.0014635.
|
| 396 |
Potent antimyeloma activity of a novel ERK5/CDK inhibitor.Clin Cancer Res. 2013 May 15;19(10):2677-87. doi: 10.1158/1078-0432.CCR-12-2118. Epub 2013 Mar 26.
|
| 397 |
XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach.J Proteomics. 2019 Oct 30;209:103504. doi: 10.1016/j.jprot.2019.103504. Epub 2019 Aug 26.
|
| 398 |
Promiscuity of translocation partners in multiple myeloma.J Cell Biochem. 2010 Apr 15;109(6):1085-94. doi: 10.1002/jcb.22499.
|
| 399 |
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage.Leukemia. 2006 Apr;20(4):689-95. doi: 10.1038/sj.leu.2404138.
|
| 400 |
Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.Oncogene. 2017 Oct 5;36(40):5631-5638. doi: 10.1038/onc.2017.172. Epub 2017 Jun 5.
|
| 401 |
T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.Biol Blood Marrow Transplant. 2020 Jan;26(1):7-15. doi: 10.1016/j.bbmt.2019.08.009. Epub 2019 Aug 21.
|
| 402 |
An Lysophosphatidic Acid Receptors 1 and 3 Axis Governs Cellular Senescence of Mesenchymal Stromal Cells and Promotes Growth and Vascularization of Multiple Myeloma.Stem Cells. 2017 Mar;35(3):739-753. doi: 10.1002/stem.2499. Epub 2016 Sep 29.
|
| 403 |
Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data.Biomed Res Int. 2018 Dec 16;2018:9057823. doi: 10.1155/2018/9057823. eCollection 2018.
|
| 404 |
Expression of ABCB5 gene in hematological malignances and its significance.Leuk Lymphoma. 2012 Jun;53(6):1211-5. doi: 10.3109/10428194.2011.637214. Epub 2011 Dec 7.
|
| 405 |
Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies.Biol Blood Marrow Transplant. 2016 May;22(5):843-9. doi: 10.1016/j.bbmt.2015.12.022. Epub 2015 Dec 29.
|
| 406 |
MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells.Oncogene. 2013 Jan 10;32(2):190-7. doi: 10.1038/onc.2012.43. Epub 2012 Feb 27.
|
| 407 |
Mouse and human ornithine decarboxylase genes. Methylation polymorphism and amplification.Biochem J. 1987 Feb 15;242(1):205-10. doi: 10.1042/bj2420205.
|
| 408 |
Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro.Leuk Res. 2008 Apr;32(4):611-23. doi: 10.1016/j.leukres.2007.07.009. Epub 2007 Aug 21.
|
| 409 |
A molecular compendium of genes expressed in multiple myeloma.Blood. 2002 Sep 15;100(6):2175-86. doi: 10.1182/blood-2002-01-0008.
|
| 410 |
Combined Group I and III ABO Discrepancies in Multiple Myeloma with IgG-Lambda Type: A Case Report.Med Princ Pract. 2017;26(1):90-92. doi: 10.1159/000450579. Epub 2016 Sep 5.
|
| 411 |
Restoration of the prolyl-hydroxylase domain protein-3 oxygen-sensing mechanism is responsible for regulation of HIF2 expression and induction of sensitivity of myeloma cells to hypoxia-mediated apoptosis.PLoS One. 2017 Dec 5;12(12):e0188438. doi: 10.1371/journal.pone.0188438. eCollection 2017.
|
| 412 |
MUC1-C drives MYC in multiple myeloma.Blood. 2016 May 26;127(21):2587-97. doi: 10.1182/blood-2015-07-659151. Epub 2016 Feb 23.
|
| 413 |
Polymorphisms of methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), methionine synthase reductase (MTRR), and thymidylate synthase (TYMS) in multiple myeloma risk.Leuk Res. 2008 Mar;32(3):401-5. doi: 10.1016/j.leukres.2007.06.001. Epub 2007 Jul 25.
|
| 414 |
Differential repetitive DNA methylation in multiple myeloma molecular subgroups.Carcinogenesis. 2009 Aug;30(8):1330-5. doi: 10.1093/carcin/bgp149. Epub 2009 Jun 16.
|
| 415 |
Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.Int J Cancer. 2003 Sep 1;106(3):455-7. doi: 10.1002/ijc.11247.
|
| 416 |
Association between CYP2C8 (rs1934951) polymorphism and bisphosphonate-related osteonecrosis of the jaws in patients on bisphosphonate therapy: a meta-analysis.Acta Haematol. 2013;129(2):90-5. doi: 10.1159/000342120. Epub 2012 Nov 21.
|
| 417 |
Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive rates.BMC Bioinformatics. 2016 Apr 11;17:159. doi: 10.1186/s12859-016-0997-6.
|
| 418 |
Identification of a novel murine IAP-promoted placenta-expressed gene.Nucleic Acids Res. 1991 Jul 11;19(13):3667-72. doi: 10.1093/nar/19.13.3667.
|
| 419 |
Polymorphisms of human N-acetyltransferases and cancer risk.Curr Drug Metab. 2008 Jul;9(6):520-31. doi: 10.2174/138920008784892083.
|
| 420 |
High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.Br J Haematol. 2014 Sep;166(5):711-9. doi: 10.1111/bjh.12951. Epub 2014 May 29.
|
| 421 |
Genetic polymorphism in the sulfotransferase SULT1A1 gene in cancer.Cancer Genet Cytogenet. 2005 Jul 1;160(1):55-60. doi: 10.1016/j.cancergencyto.2004.12.005.
|
| 422 |
Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.Appl Health Econ Health Policy. 2017 Feb;15(1):45-55. doi: 10.1007/s40258-016-0271-0.
|
| 423 |
Epigenetic inactivation of ADAMTS9 via promoter methylation in multiple myeloma.Mol Med Rep. 2013 Mar;7(3):1055-61. doi: 10.3892/mmr.2013.1291. Epub 2013 Jan 28.
|
| 424 |
LncRNA MALAT-1 Elevates HMGB1 to Promote Autophagy Resulting in Inhibition of Tumor Cell Apoptosis in Multiple Myeloma.J Cell Biochem. 2017 Oct;118(10):3341-3348. doi: 10.1002/jcb.25987. Epub 2017 May 3.
|
| 425 |
ANKHD1 represses p21 (WAF1/CIP1) promoter and promotes multiple myeloma cell growth.Eur J Cancer. 2015 Jan;51(2):252-9. doi: 10.1016/j.ejca.2014.11.012. Epub 2014 Dec 4.
|
| 426 |
The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.Target Oncol. 2018 Feb;13(1):39-47. doi: 10.1007/s11523-017-0538-x.
|
| 427 |
Bim is the key mediator of glucocorticoid-induced apoptosis and of its potentiation by rapamycin in human myeloma cells.Biochim Biophys Acta. 2010 Feb;1803(2):311-22. doi: 10.1016/j.bbamcr.2009.11.004. Epub 2009 Nov 13.
|
| 428 |
Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications.Leuk Lymphoma. 2012 Sep;53(9):1709-13. doi: 10.3109/10428194.2012.661854. Epub 2012 Mar 13.
|
| 429 |
Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production.J Bone Miner Metab. 2009;27(1):16-23. doi: 10.1007/s00774-008-0012-z. Epub 2008 Dec 5.
|
| 430 |
Cancer cell-associated cytoplasmic B7-H4 is induced by hypoxia through hypoxia-inducible factor-1 and promotes cancer cell proliferation.Biochem Biophys Res Commun. 2015 Apr 3;459(2):277-283. doi: 10.1016/j.bbrc.2015.02.098. Epub 2015 Feb 26.
|
| 431 |
Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms.Mod Pathol. 2018 Jun;31(6):881-889. doi: 10.1038/s41379-018-0011-0. Epub 2018 Feb 5.
|
| 432 |
Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders.Leuk Lymphoma. 2018 Nov;59(11):2660-2669. doi: 10.1080/10428194.2018.1443450. Epub 2018 Apr 4.
|
| 433 |
CIP2A regulates proliferation and apoptosis of multiple myeloma cells.Mol Med Rep. 2016 Sep;14(3):2705-9. doi: 10.3892/mmr.2016.5553. Epub 2016 Jul 27.
|
| 434 |
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010 Nov;11(11):1057-65. doi: 10.1016/S1470-2045(10)70206-0. Epub 2010 Sep 21.
|
| 435 |
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.Cancer Med. 2014 Oct;3(5):1275-83. doi: 10.1002/cam4.276. Epub 2014 Jun 10.
|
| 436 |
DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway.Leukemia. 2009 Feb;23(2):383-90. doi: 10.1038/leu.2008.285. Epub 2008 Oct 16.
|
| 437 |
eIF4E and eIF4GI have distinct and differential imprints on multiple myeloma's proteome and signaling.Oncotarget. 2015 Feb 28;6(6):4315-29. doi: 10.18632/oncotarget.3008.
|
| 438 |
RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.Leukemia. 2017 Aug;31(8):1706-1714. doi: 10.1038/leu.2016.370. Epub 2016 Dec 2.
|
| 439 |
Syndecan-1 promotes Wnt/-catenin signaling in multiple myeloma by presenting Wnts and R-spondins.Blood. 2018 Mar 1;131(9):982-994. doi: 10.1182/blood-2017-07-797050. Epub 2017 Dec 6.
|
| 440 |
Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow.Leukemia. 2015 Sep;29(9):1901-8. doi: 10.1038/leu.2015.68. Epub 2015 Mar 10.
|
| 441 |
Down-regulated G protein-coupled receptor kinase 6 leads to apoptosis in multiple myeloma MM1R cells.Exp Ther Med. 2018 Nov;16(5):4253-4259. doi: 10.3892/etm.2018.6722. Epub 2018 Sep 11.
|
| 442 |
The inhibitor of growth 1 (ING1) proteins suppress angiogenesis and differentially regulate angiopoietin expression in glioblastoma cells.Oncol Res. 2009;18(2-3):95-105. doi: 10.3727/096504009789954645.
|
| 443 |
Macrophage Inhibitory Factor-1 (MIF-1) controls the plasticity of multiple myeloma tumor cells.PLoS One. 2018 Nov 1;13(11):e0206368. doi: 10.1371/journal.pone.0206368. eCollection 2018.
|
| 444 |
Quercetin suppresses the proliferation of multiple myeloma cells by down-regulating IQ motif-containing GTPase activating protein 1 expression and extracellular signal-regulated kinase activation.Leuk Lymphoma. 2014 Nov;55(11):2597-604. doi: 10.3109/10428194.2013.879128. Epub 2014 Mar 7.
|
| 445 |
An IgG1 Version of the Anti-transferrin Receptor 1 Antibody ch128.1 Shows Significant Antitumor Activity Against Different Xenograft Models of Multiple Myeloma: A Brief Communication.J Immunother. 2020 Feb/Mar;43(2):48-52. doi: 10.1097/CJI.0000000000000304.
|
| 446 |
Role of Galectins in Multiple Myeloma.Int J Mol Sci. 2017 Dec 17;18(12):2740. doi: 10.3390/ijms18122740.
|
| 447 |
Small interfering RNA-mediated silencing of nicotinamide phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) induce growth inhibition and apoptosis in human multiple myeloma cells: A preliminary study.Bosn J Basic Med Sci. 2016 Nov 10;16(4):268-275. doi: 10.17305/bjbms.2016.1568.
|
| 448 |
Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma.Cancer Sci. 2019 Aug;110(8):2600-2606. doi: 10.1111/cas.14109. Epub 2019 Jul 11.
|
| 449 |
Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays.Am J Surg Pathol. 2007 May;31(5):690-6. doi: 10.1097/01.pas.0000213399.87816.56.
|
| 450 |
Differential Expression of Non-Shelterin Genes Associated with High Telomerase Levels and Telomere Shortening in Plasma Cell Disorders.PLoS One. 2015 Sep 14;10(9):e0137972. doi: 10.1371/journal.pone.0137972. eCollection 2015.
|
| 451 |
MYEOV is a prognostic factor in multiple myeloma.Exp Hematol. 2010 Dec;38(12):1189-1198.e3. doi: 10.1016/j.exphem.2010.09.002. Epub 2010 Sep 18.
|
| 452 |
High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature.Leuk Lymphoma. 2013 Aug;54(8):1652-7. doi: 10.3109/10428194.2012.753445. Epub 2012 Dec 27.
|
| 453 |
Frequent PVT1 rearrangement and novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in multiple myeloma with 8q24 abnormality.Cancer Res. 2012 Oct 1;72(19):4954-62. doi: 10.1158/0008-5472.CAN-12-0213. Epub 2012 Aug 6.
|
| 454 |
The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP.Ann Hematol. 2011 Jun;90(6):675-84. doi: 10.1007/s00277-010-1105-z. Epub 2010 Nov 3.
|
| 455 |
MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.Oncotarget. 2016 Feb 9;7(6):7149-60. doi: 10.18632/oncotarget.6880.
|
| 456 |
Expression of RAN, ZHX-2, and CHC1L genes in multiple myeloma patients and in myeloma cell lines treated with HDAC and Dnmts inhibitors.Neoplasma. 2010;57(5):482-7. doi: 10.4149/neo_2010_05_482.
|
| 457 |
Unraveling the Prenylation-Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors.J Med Chem. 2018 Aug 9;61(15):6904-6917. doi: 10.1021/acs.jmedchem.8b00886. Epub 2018 Jul 25.
|
| 458 |
Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression.Haematologica. 2017 Jul;102(7):1273-1280. doi: 10.3324/haematol.2016.154062. Epub 2017 Mar 30.
|
| 459 |
Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types.PLoS One. 2015 May 28;10(5):e0127828. doi: 10.1371/journal.pone.0127828. eCollection 2015.
|
| 460 |
Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.Scand J Immunol. 2013 Aug;78(2):130-9. doi: 10.1111/sji.12069.
|
| 461 |
Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance: a genome-wide genetic interaction study.Mol Med. 2018 Jun 11;24(1):30. doi: 10.1186/s10020-018-0031-8.
|
| 462 |
Sclerostin is overexpressed by plasma cells from multiple myeloma patients.Ann N Y Acad Sci. 2011 Nov;1237:19-23. doi: 10.1111/j.1749-6632.2011.06196.x.
|
| 463 |
The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma.Mol Cancer. 2014 Feb 5;13:25. doi: 10.1186/1476-4598-13-25.
|
| 464 |
Orai1 and Stim1 Mediate the Majority of Store-Operated Calcium Entry in Multiple Myeloma and Have Strong Implications for Adverse Prognosis.Cell Physiol Biochem. 2018;48(6):2273-2285. doi: 10.1159/000492645. Epub 2018 Aug 16.
|
| 465 |
TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma.Lab Invest. 2001 Apr;81(4):555-64. doi: 10.1038/labinvest.3780264.
|
| 466 |
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.Blood. 2017 Mar 9;129(10):1308-1319. doi: 10.1182/blood-2016-09-738500. Epub 2017 Jan 12.
|
| 467 |
LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p.Cell Death Dis. 2019 Feb 6;10(2):106. doi: 10.1038/s41419-018-1219-0.
|
| 468 |
Downregulation of DCC sensitizes multiple myeloma cells to bortezomib treatment.Mol Med Rep. 2019 Jun;19(6):5023-5029. doi: 10.3892/mmr.2019.10142. Epub 2019 Apr 9.
|
| 469 |
EPS8-mediated regulation of multiple myeloma cell growth and survival.Am J Cancer Res. 2019 Aug 1;9(8):1622-1634. eCollection 2019.
|
| 470 |
Difference in megakaryocyte expression of GATA-1, IL-6, and IL-8 associated with maintenance of platelet counts in patients with plasma cell neoplasm with dysmegakaryopoiesis.Exp Hematol. 2019 May;73:13-17.e2. doi: 10.1016/j.exphem.2019.02.005. Epub 2019 Feb 27.
|
| 471 |
The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):138-159. doi: 10.1016/j.bbcan.2018.11.007. Epub 2018 Dec 30.
|
| 472 |
Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model.Biomolecules. 2019 Jul 7;9(7):262. doi: 10.3390/biom9070262.
|
| 473 |
Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups.Curr Top Med Chem. 2019;19(3):223-241. doi: 10.2174/1568026619666190122144949.
|
| 474 |
miR-22 suppresses DNA ligase III addiction in multiple myeloma.Leukemia. 2019 Feb;33(2):487-498. doi: 10.1038/s41375-018-0238-2. Epub 2018 Aug 17.
|
| 475 |
Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.FASEB J. 2019 Aug;33(8):9489-9504. doi: 10.1096/fj.201900319R. Epub 2019 May 24.
|
| 476 |
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice.J Vis Exp. 2019 Jan 7;(143):10.3791/58056. doi: 10.3791/58056.
|
| 477 |
Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor.Eur J Med Chem. 2020 Jan 15;186:111906. doi: 10.1016/j.ejmech.2019.111906. Epub 2019 Nov 21.
|
| 478 |
I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma.Biosci Rep. 2019 May 14;39(5):BSR20181245. doi: 10.1042/BSR20181245. Print 2019 May 31.
|
| 479 |
MiR-9 promotes multiple myeloma progression by regulating TRIM56/NF-B pathway.Cell Biol Int. 2019 Nov;43(11):1223-1233. doi: 10.1002/cbin.11104. Epub 2019 Jul 17.
|
| 480 |
Role of apurinic/apyrimidinic nucleases in the regulation of homologous recombination in myeloma: mechanisms and translational significance.Blood Cancer J. 2018 Sep 25;8(10):92. doi: 10.1038/s41408-018-0129-9.
|
| 481 |
Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.Sci Rep. 2019 May 9;9(1):7122. doi: 10.1038/s41598-019-43575-y.
|
| 482 |
ARNT/HIF-1 links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma.Cancer Med. 2018 Aug;7(8):3899-3911. doi: 10.1002/cam4.1596. Epub 2018 Jun 21.
|
| 483 |
Differential expression of serum proteins in multiple myeloma.Exp Ther Med. 2019 Jan;17(1):649-656. doi: 10.3892/etm.2018.7010. Epub 2018 Nov 23.
|
| 484 |
The Expression of Actin-Related Protein 2/3 Complex Subunit 5 (ARPC5) Expression in Multiple Myeloma and its Prognostic Significance.Med Sci Monit. 2018 Sep 11;24:6340-6348. doi: 10.12659/MSM.908944.
|
| 485 |
Prediction and prognostic significance of BCAR3 expression in patients with multiple myeloma.J Transl Med. 2018 Dec 18;16(1):363. doi: 10.1186/s12967-018-1728-8.
|
| 486 |
Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease.Nat Commun. 2019 Oct 4;10(1):4533. doi: 10.1038/s41467-019-12296-1.
|
| 487 |
MicroRNA-324-5p suppresses the migration and invasion of MM cells by inhibiting the SCF(-TrCP) E3 ligase.Oncol Lett. 2018 Oct;16(4):5331-5338. doi: 10.3892/ol.2018.9245. Epub 2018 Aug 1.
|
| 488 |
Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN1 expression.Oncol Lett. 2018 Jan;15(1):1287-1296. doi: 10.3892/ol.2017.7424. Epub 2017 Nov 15.
|
| 489 |
MicroRNA-532 exerts oncogenic functions in t(4;14) multiple myeloma by targeting CAMK2N1.Hum Cell. 2019 Oct;32(4):529-539. doi: 10.1007/s13577-019-00276-y. Epub 2019 Aug 26.
|
| 490 |
The Genetic Polymorphisms of NLRP3 Inflammasome Associated with T Helper Cells in Patients with Multiple Myeloma.J Immunol Res. 2018 Aug 23;2018:7569809. doi: 10.1155/2018/7569809. eCollection 2018.
|
| 491 |
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.J Clin Invest. 2019 Mar 21;129(6):2210-2221. doi: 10.1172/JCI126397.
|
| 492 |
Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples.Haematologica. 2019 Dec;104(12):2456-2464. doi: 10.3324/haematol.2019.216895. Epub 2019 Apr 4.
|
| 493 |
Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. Eur J Haematol. 2010 Mar;84(3):212-22. doi: 10.1111/j.1600-0609.2009.01381.x. Epub 2009 Nov 17.
|
| 494 |
Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide.Cancer Res. 2018 Apr 1;78(7):1766-1778. doi: 10.1158/0008-5472.CAN-17-2446. Epub 2018 Jan 23.
|
| 495 |
Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma.Int J Hematol. 2019 Jul;110(1):69-76. doi: 10.1007/s12185-019-02649-3. Epub 2019 May 21.
|
| 496 |
Visualizing collagen proteolysis by peptide hybridization: From 3D cell culture to in vivo imaging.Biomaterials. 2018 Nov;183:67-76. doi: 10.1016/j.biomaterials.2018.08.039. Epub 2018 Aug 22.
|
| 497 |
ClC5 Decreases the Sensitivity of Multiple Myeloma Cells to Bortezomib via Promoting Prosurvival Autophagy.Oncol Res. 2018 Apr 10;26(3):421-429. doi: 10.3727/096504017X15049221237147. Epub 2017 Sep 11.
|
| 498 |
Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.Cancer Sci. 2017 Apr;108(4):641-652. doi: 10.1111/cas.13183. Epub 2017 Apr 20.
|
| 499 |
Synthesis, Computational Docking Study, and Biological Evaluation of a Library of Heterocyclic Curcuminoids with Remarkable Antitumor Activity.ChemMedChem. 2018 Sep 19;13(18):1895-1908. doi: 10.1002/cmdc.201800320. Epub 2018 Aug 5.
|
| 500 |
Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study).Hematol Oncol. 2018 Feb;36(1):202-209. doi: 10.1002/hon.2452. Epub 2017 Jul 6.
|
| 501 |
Wnt and BMP signaling pathways co-operatively induce the differentiation of multiple myeloma mesenchymal stem cells into osteoblasts by upregulating EMX2.J Cell Biochem. 2019 Apr;120(4):6515-6527. doi: 10.1002/jcb.27942. Epub 2018 Nov 18.
|
| 502 |
Nucleotide excision repair is a potential therapeutic target in multiple myeloma.Leukemia. 2018 Jan;32(1):111-119. doi: 10.1038/leu.2017.182. Epub 2017 Jun 7.
|
| 503 |
Epigenetic silencing of EVL/miR-342 in multiple myeloma.Transl Res. 2018 Feb;192:46-53. doi: 10.1016/j.trsl.2017.11.005. Epub 2017 Nov 23.
|
| 504 |
The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation.Haematologica. 2020 Mar;105(3):774-783. doi: 10.3324/haematol.2019.222133. Epub 2019 Jun 20.
|
| 505 |
Novel flavagline-like compounds with potent Fli-1 inhibitory activity suppress diverse types of leukemia.FEBS J. 2018 Dec;285(24):4631-4645. doi: 10.1111/febs.14690. Epub 2018 Nov 20.
|
| 506 |
GENESIS: Phase III trial evaluating BL-8040+G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma.Future Oncol. 2019 Nov;15(31):3555-3563. doi: 10.2217/fon-2019-0380. Epub 2019 Sep 9.
|
| 507 |
Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type.Virchows Arch. 2018 Dec;473(6):749-757. doi: 10.1007/s00428-018-2434-x. Epub 2018 Aug 27.
|
| 508 |
Intermediate-dose cytarabine plus G-CSF as mobilization regimen for newly diagnosed multiple myeloma and heavily pre-treated patients with hematological and non-hematological malignancies.Transfus Apher Sci. 2019 Jun;58(3):318-322. doi: 10.1016/j.transci.2019.03.018. Epub 2019 Mar 29.
|
| 509 |
Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-B activity and increases drug resistance in multiple myeloma.J Biol Chem. 2018 Feb 16;293(7):2452-2465. doi: 10.1074/jbc.RA117.000667. Epub 2017 Dec 26.
|
| 510 |
Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression.Cell Cycle. 2018;17(3):319-329. doi: 10.1080/15384101.2017.1407893. Epub 2018 Jan 29.
|
| 511 |
HOXC10 Regulates Osteogenesis of Mesenchymal Stromal Cells Through Interaction with Its Natural Antisense Transcript lncHOXC-AS3.Stem Cells. 2019 Feb;37(2):247-256. doi: 10.1002/stem.2925. Epub 2018 Dec 2.
|
| 512 |
A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.Blood Cancer J. 2018 Mar 21;8(3):35. doi: 10.1038/s41408-018-0062-y.
|
| 513 |
A role for IL-34 in osteolytic disease of multiple myeloma.Blood Adv. 2019 Feb 26;3(4):541-551. doi: 10.1182/bloodadvances.2018020008.
|
| 514 |
Search for rare protein altering variants influencing susceptibility to multiple myeloma.Oncotarget. 2017 May 30;8(22):36203-36210. doi: 10.18632/oncotarget.15874.
|
| 515 |
Regions of homozygosity as risk factors for multiple myeloma.Ann Hum Genet. 2019 Jul;83(4):231-238. doi: 10.1111/ahg.12304. Epub 2019 Feb 15.
|
| 516 |
Circulating CD3(+)CD4(+)CD161(+) Cells Are Associated with Early Complications after Autologous Stem Cell Transplantation in Multiple Myeloma.Biomed Res Int. 2018 Jan 1;2018:5097325. doi: 10.1155/2018/5097325. eCollection 2018.
|
| 517 |
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients.Blood Cancer J. 2019 Jan 29;9(2):13. doi: 10.1038/s41408-019-0174-z.
|
| 518 |
Focusing on long non-coding RNA dysregulation in newly diagnosed multiple myeloma.Life Sci. 2018 Mar 1;196:133-142. doi: 10.1016/j.lfs.2018.01.025. Epub 2018 Feb 3.
|
| 519 |
Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination.J Med Genet. 2002 Dec;39(12):900-5. doi: 10.1136/jmg.39.12.900.
|
| 520 |
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression.Nat Commun. 2018 Apr 25;9(1):1649. doi: 10.1038/s41467-018-04082-2.
|
| 521 |
A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenstrm Macroglobulinemia.Clin Cancer Res. 2019 Aug 15;25(16):4907-4916. doi: 10.1158/1078-0432.CCR-18-3728. Epub 2019 May 29.
|
| 522 |
Young female patients with multiple myeloma have low occurrence of osteolytic lesion.Bone. 2018 May;110:21-28. doi: 10.1016/j.bone.2018.01.021. Epub 2018 Feb 3.
|
| 523 |
MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma.Nucleic Acids Res. 2017 Mar 17;45(5):2396-2407. doi: 10.1093/nar/gkw1184.
|
| 524 |
Management of Newly Diagnosed Elderly Multiple Myeloma Patients.Curr Oncol Rep. 2019 May 24;21(7):64. doi: 10.1007/s11912-019-0804-4.
|
| 525 |
Synergistic effects of rmhTRAIL and 17-AAG on the proliferation and apoptosis of multiple myeloma cells.Hematology. 2018 Oct;23(9):620-625. doi: 10.1080/10245332.2018.1449338. Epub 2018 Mar 22.
|
| 526 |
MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells.Immunol Cell Biol. 2017 Aug;95(7):611-619. doi: 10.1038/icb.2017.18. Epub 2017 Mar 17.
|
| 527 |
Constraints on signaling network logic reveal functional subgraphs on Multiple Myeloma OMIC data.BMC Syst Biol. 2018 Mar 21;12(Suppl 3):32. doi: 10.1186/s12918-018-0551-4.
|
| 528 |
Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis.Blood. 2018 Sep 20;132(12):1304-1317. doi: 10.1182/blood-2018-02-832576. Epub 2018 Jul 30.
|
| 529 |
Breast cancer and synchronous multiple myeloma as a diagnostic challenge: Case report and review of literature.Curr Probl Cancer. 2018 Mar-Apr;42(2):231-234. doi: 10.1016/j.currproblcancer.2017.11.001. Epub 2017 Nov 22.
|
| 530 |
Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma.Int J Hematol. 2017 Mar;105(3):318-325. doi: 10.1007/s12185-016-2139-3. Epub 2016 Nov 15.
|
| 531 |
High expression of nucleoporin 133 mRNA in bone marrow CD138+ cells is a poor prognostic factor in multiple myeloma.Oncotarget. 2018 May 18;9(38):25127-25135. doi: 10.18632/oncotarget.25350. eCollection 2018 May 18.
|
| 532 |
Knockdown of NUPR1 inhibits the growth of U266 and RPMI8226 multiple myeloma cell lines via activating PTEN and caspase activationdependent apoptosis.Oncol Rep. 2018 Sep;40(3):1487-1494. doi: 10.3892/or.2018.6544. Epub 2018 Jul 4.
|
| 533 |
Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma.Leukemia. 2017 Feb;31(2):373-381. doi: 10.1038/leu.2016.187. Epub 2016 Jul 11.
|
| 534 |
Profilin 1 induces drug resistance through Beclin1 complex-mediated autophagy in multiple myeloma.Cancer Sci. 2018 Sep;109(9):2706-2716. doi: 10.1111/cas.13711. Epub 2018 Jul 27.
|
| 535 |
PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation.Blood. 2019 Oct 3;134(14):1176-1189. doi: 10.1182/blood.2019000578. Epub 2019 Aug 5.
|
| 536 |
The transmembrane protein TMEPAI induces myeloma cell apoptosis by promoting degradation of the c-Maf transcription factor.J Biol Chem. 2018 Apr 20;293(16):5847-5859. doi: 10.1074/jbc.RA117.000972. Epub 2018 Feb 21.
|
| 537 |
Saposin C is a frequent target of paraproteins in Gaucher disease-associated MGUS/multiple myeloma.Br J Haematol. 2019 Feb;184(3):384-391. doi: 10.1111/bjh.15659. Epub 2018 Nov 18.
|
| 538 |
Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy.Mol Cancer Res. 2019 Nov;17(11):2331-2340. doi: 10.1158/1541-7786.MCR-19-0487. Epub 2019 Aug 13.
|
| 539 |
Exosome-Transmitted PSMA3 and PSMA3-AS1 Promote Proteasome Inhibitor Resistance in Multiple Myeloma.Clin Cancer Res. 2019 Mar 15;25(6):1923-1935. doi: 10.1158/1078-0432.CCR-18-2363. Epub 2019 Jan 4.
|
| 540 |
Knockdown of REG inhibits the proliferation and migration and promotes the apoptosis of multiple myeloma cells by downregulating NF-B signal pathway.Hematology. 2018 Jun;23(5):277-283. doi: 10.1080/10245332.2017.1385194. Epub 2017 Oct 11.
|
| 541 |
GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study.Clin Exp Nephrol. 2019 Feb;23(2):199-206. doi: 10.1007/s10157-018-1626-7. Epub 2018 Aug 20.
|
| 542 |
Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.Cancer Res. 2018 Mar 1;78(5):1155-1168. doi: 10.1158/0008-5472.CAN-17-1544. Epub 2017 Dec 19.
|
| 543 |
Prognosis value of RBBP8 expression in plasma cell myeloma.Cancer Gene Ther. 2020 Feb;27(1-2):22-29. doi: 10.1038/s41417-018-0069-3. Epub 2019 Jan 9.
|
| 544 |
Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy.Haematologica. 2020 Jun;105(6):1630-1640. doi: 10.3324/haematol.2019.218289. Epub 2019 Jul 9.
|
| 545 |
Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS.Leukemia. 2018 Nov;32(11):2471-2482. doi: 10.1038/s41375-018-0140-y. Epub 2018 Apr 24.
|
| 546 |
Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-B signaling pathway.Protein Cell. 2018 Sep;9(9):770-784. doi: 10.1007/s13238-017-0500-9. Epub 2018 Feb 13.
|
| 547 |
RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.Leukemia. 2017 Oct;31(10):2104-2113. doi: 10.1038/leu.2017.54. Epub 2017 Feb 10.
|
| 548 |
RGS1 expression is associated with poor prognosis in multiple myeloma.J Clin Pathol. 2017 Mar;70(3):202-207. doi: 10.1136/jclinpath-2016-203713. Epub 2016 Jul 21.
|
| 549 |
The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma.Blood Cancer J. 2018 Feb 13;8(2):20. doi: 10.1038/s41408-018-0053-z.
|
| 550 |
High Expression Levels of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 and Semaphorin 5A Indicate Poor Prognosis in Multiple Myeloma.Acta Haematol. 2020;143(3):279-288. doi: 10.1159/000502404. Epub 2019 Oct 9.
|
| 551 |
Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo.Neoplasia. 2019 Aug;21(8):777-787. doi: 10.1016/j.neo.2019.05.006. Epub 2019 Jun 24.
|
| 552 |
Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p.BMC Cancer. 2019 Oct 10;19(1):937. doi: 10.1186/s12885-019-6088-0.
|
| 553 |
Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells.Bone. 2019 May;122:82-92. doi: 10.1016/j.bone.2019.02.012. Epub 2019 Feb 15.
|
| 554 |
NEAT1 promotes cell proliferation in multiple myeloma by activating PI3K/AKT pathway.Eur Rev Med Pharmacol Sci. 2018 Oct;22(19):6403-6411. doi: 10.26355/eurrev_201810_16053.
|
| 555 |
MicroRNA-765 is pregulated in multiple myeloma and serves an oncogenic role by directly targeting SOX6.Exp Ther Med. 2019 Jun;17(6):4741-4747. doi: 10.3892/etm.2019.7473. Epub 2019 Apr 10.
|
| 556 |
Thiasyrbactins Induce Cell Death via Proteasome Inhibition in Multiple Myeloma Cells.Anticancer Res. 2018 Oct;38(10):5607-5613. doi: 10.21873/anticanres.12895.
|
| 557 |
The mechanism of SP1/p300 complex promotes proliferation of multiple myeloma cells through regulating IQGAP1 transcription.Biomed Pharmacother. 2019 Nov;119:109434. doi: 10.1016/j.biopha.2019.109434. Epub 2019 Sep 16.
|
| 558 |
Identification of miRSNPs associated with the risk of multiple myeloma.Int J Cancer. 2017 Feb 1;140(3):526-534. doi: 10.1002/ijc.30465. Epub 2016 Nov 9.
|
| 559 |
Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.Sci Rep. 2019 Dec 2;9(1):18062. doi: 10.1038/s41598-019-54407-4.
|
| 560 |
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.Expert Rev Mol Diagn. 2018 Jul;18(7):675-683. doi: 10.1080/14737159.2018.1470929. Epub 2018 May 3.
|
| 561 |
TRIM13 inhibited cell proliferation and induced cell apoptosis by regulating NF-B pathway in non-small-cell lung carcinoma cells.Gene. 2019 Oct 5;715:144015. doi: 10.1016/j.gene.2019.144015. Epub 2019 Jul 26.
|
| 562 |
Nitroxoline shows antimyeloma activity by targeting the TRIM25/p53 axle.Anticancer Drugs. 2017 Apr;28(4):376-383. doi: 10.1097/CAD.0000000000000466.
|
| 563 |
Expression of p170 protein in multiple myeloma: a clinical study.Hematol Oncol. 1992 May-Aug;10(3-4):213-20. doi: 10.1002/hon.2900100312.
|
| 564 |
Che-1 gene silencing induces osteosarcoma cell apoptosis by inhibiting mutant p53 expression.Biochem Biophys Res Commun. 2016 Apr 22;473(1):168-173. doi: 10.1016/j.bbrc.2016.03.073. Epub 2016 Mar 21.
|
| 565 |
BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome.Blood. 1998 Oct 1;92(7):2294-302.
|
| 566 |
DCZ0814 induces apoptosis and G0/G1 phase cell cycle arrest in myeloma by dual inhibition of mTORC1/2.Cancer Manag Res. 2019 May 27;11:4797-4808. doi: 10.2147/CMAR.S194202. eCollection 2019.
|
| 567 |
IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification.Haematologica. 2020 May;105(5):1391-1404. doi: 10.3324/haematol.2019.221176. Epub 2019 Aug 14.
|
| 568 |
Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.BMC Cancer. 2016 May 3;16:297. doi: 10.1186/s12885-016-2331-0.
|
| 569 |
Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells.Blood. 1991 Aug 1;78(3):711-9.
|
| 570 |
Urinary excretion of low molecular weight proteins in patients with pure monoclonal light chain proteinuria.J Nephrol. 2007 Nov-Dec;20(6):683-8.
|
| 571 |
Host genetic susceptibility to Clostridium difficile infections in patients undergoing autologous stem cell transplantation: a genome-wide association study.Support Care Cancer. 2018 Sep;26(9):3127-3134. doi: 10.1007/s00520-018-4173-6. Epub 2018 Mar 28.
|
| 572 |
Scutellarein selectively targets multiple myeloma cells by increasing mitochondrial superoxide production and activating intrinsic apoptosis pathway.Biomed Pharmacother. 2019 Jan;109:2109-2118. doi: 10.1016/j.biopha.2018.09.024. Epub 2018 Nov 26.
|
| 573 |
Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy.J Clin Invest. 2016 Apr 1;126(4):1300-10. doi: 10.1172/JCI84620. Epub 2016 Feb 29.
|
| 574 |
Genomic hypomethylation in human chronic lymphocytic leukemia.Blood. 1992 Oct 15;80(8):2074-80.
|
| 575 |
Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells.PLoS One. 2011;6(10):e25820. doi: 10.1371/journal.pone.0025820. Epub 2011 Oct 18.
|
| 576 |
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.Nat Commun. 2016 Jul 1;7:12050. doi: 10.1038/ncomms12050.
|
| 577 |
A novel xenograft mouse model for testing approaches targeting human kappa light-chain diseases.Gene Ther. 2019 May;26(5):187-197. doi: 10.1038/s41434-019-0070-y. Epub 2019 Mar 29.
|
| 578 |
Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by MafB.Cell Cycle. 2012 Oct 15;11(20):3896-900. doi: 10.4161/cc.22186. Epub 2012 Sep 14.
|
| 579 |
Host-related immunodeficiency in the development of multiple myeloma.Leuk Lymphoma. 2018 May;59(5):1127-1132. doi: 10.1080/10428194.2017.1361026. Epub 2017 Aug 9.
|
| 580 |
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells.Immunity. 2007 Dec;27(6):965-74. doi: 10.1016/j.immuni.2007.10.010. Epub 2007 Dec 6.
|
| 581 |
Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity.Cancer Chemother Pharmacol. 2011 Jan;67(1):13-25. doi: 10.1007/s00280-010-1273-5. Epub 2010 Feb 23.
|
| 582 |
Bcl-B expression in human epithelial and nonepithelial malignancies.Clin Cancer Res. 2008 May 15;14(10):3011-21. doi: 10.1158/1078-0432.CCR-07-1955.
|
| 583 |
High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.Eur J Haematol. 2009 May;82(5):354-63. doi: 10.1111/j.1600-0609.2009.01225.x. Epub 2009 Jan 13.
|
| 584 |
Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.Breast Cancer Res. 2015 Sep 17;17:128. doi: 10.1186/s13058-015-0630-z.
|
| 585 |
Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies.Ann Oncol. 2019 Apr 1;30(4):528-541. doi: 10.1093/annonc/mdz045.
|
| 586 |
Transcription factor MIST1 in terminal differentiation of mouse and human plasma cells.Physiol Genomics. 2011 Feb 11;43(3):174-86. doi: 10.1152/physiolgenomics.00084.2010. Epub 2010 Nov 23.
|
| 587 |
Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.Leuk Res. 2011 Dec;35(12):1637-43. doi: 10.1016/j.leukres.2011.07.016. Epub 2011 Aug 3.
|
| 588 |
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.Blood. 2009 Apr 30;113(18):4309-18. doi: 10.1182/blood-2008-10-183772. Epub 2009 Feb 4.
|
| 589 |
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.Br J Haematol. 2014 Jan;164(2):233-44. doi: 10.1111/bjh.12622. Epub 2013 Oct 28.
|
| 590 |
Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells.Mol Ther. 2008 Feb;16(2):269-79. doi: 10.1038/sj.mt.6300369. Epub 2007 Dec 11.
|
| 591 |
Cost-Effectiveness of Novel Agents in Medicare Patients with Multiple Myeloma: Findings from a U.S. Payer's Perspective.J Manag Care Spec Pharm. 2017 Aug;23(8):831-843. doi: 10.18553/jmcp.2017.23.8.831.
|
| 592 |
A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.Hum Mol Genet. 2009 Jun 1;18(11):1951-61. doi: 10.1093/hmg/ddp116. Epub 2009 Mar 13.
|
| 593 |
The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma.Oncotarget. 2017 Oct 31;8(59):100280-100287. doi: 10.18632/oncotarget.22213. eCollection 2017 Nov 21.
|
| 594 |
CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.Oncotarget. 2016 Nov 29;7(48):78605-78618. doi: 10.18632/oncotarget.12522.
|
| 595 |
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.Leukemia. 2018 Jan;32(1):102-110. doi: 10.1038/leu.2017.179. Epub 2017 Jun 6.
|
| 596 |
Regulation of multiple myeloma survival and progression by CD1d.Blood. 2009 Mar 12;113(11):2498-507. doi: 10.1182/blood-2008-06-161281. Epub 2008 Dec 3.
|
| 597 |
Key Role of the CD56(low)CD16(low) Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells.Cancers (Basel). 2018 Nov 29;10(12):473. doi: 10.3390/cancers10120473.
|
| 598 |
An unusual presentation of multiple myeloma with unilateral sudden vision loss: A case report.Medicine (Baltimore). 2017 Jun;96(25):e7277. doi: 10.1097/MD.0000000000007277.
|
| 599 |
Expression of CD81 and CD117 in plasma cell myeloma and the relationship to prognosis.Cancer Med. 2018 Dec;7(12):5920-5927. doi: 10.1002/cam4.1840. Epub 2018 Oct 24.
|
| 600 |
Tetraspanins affect myeloma cell fate via Akt signaling and FoxO activation.Cell Signal. 2008 Dec;20(12):2309-16. doi: 10.1016/j.cellsig.2008.08.018. Epub 2008 Aug 31.
|
| 601 |
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression.Nat Commun. 2016 Nov 24;7:13656. doi: 10.1038/ncomms13656.
|
| 602 |
Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. J Clin Pathol. 2007 Jun;60(6):664-9. doi: 10.1136/jcp.2006.038331.
|
| 603 |
Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies.Leukemia. 1996 Dec;10(12):1897-900.
|
| 604 |
Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol. 2013 Apr;88(4):265-72.
|
| 605 |
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.Nat Commun. 2018 Sep 13;9(1):3707. doi: 10.1038/s41467-018-04989-w.
|
| 606 |
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.Leukemia. 2017 Aug;31(8):1743-1751. doi: 10.1038/leu.2016.388. Epub 2016 Dec 27.
|
| 607 |
Cell adhesion induces overexpression of chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L) and contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma cells.Leuk Res. 2016 Aug;47:54-62. doi: 10.1016/j.leukres.2016.05.007. Epub 2016 May 12.
|
| 608 |
Cytokine-induced apoptosis inhibitor 1 inhibits the growth and proliferation of multiple myeloma.Mol Med Rep. 2015 Aug;12(2):2056-62. doi: 10.3892/mmr.2015.3656. Epub 2015 Apr 22.
|
| 609 |
Regulation of cellular processes by interleukin-16 in homeostasis and cancer.J Cell Physiol. 2014 Feb;229(2):139-47. doi: 10.1002/jcp.24441.
|
| 610 |
MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma.Mol Immunol. 2007 Apr;44(11):2923-32. doi: 10.1016/j.molimm.2007.01.009. Epub 2007 Feb 14.
|
| 611 |
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.Mol Cancer Ther. 2009 Sep;8(9):2616-24. doi: 10.1158/1535-7163.MCT-09-0483. Epub 2009 Sep 1.
|
| 612 |
Expression of a buckwheat trypsin inhibitor gene in Escherichia coli and its effect on multiple myeloma IM-9 cell proliferation.Acta Biochim Biophys Sin (Shanghai). 2007 Sep;39(9):701-7. doi: 10.1111/j.1745-7270.2007.00332.x.
|
| 613 |
Caspase polymorphisms and genetic susceptibility to multiple myeloma.Hematol Oncol. 2008 Sep;26(3):148-51. doi: 10.1002/hon.852.
|
| 614 |
Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells.J Enzyme Inhib Med Chem. 2019 Dec;34(1):1307-1313. doi: 10.1080/14756366.2019.1594802.
|
| 615 |
CUL4A as a marker and potential therapeutic target in multiple myeloma.Tumour Biol. 2017 Jul;39(7):1010428317703923. doi: 10.1177/1010428317703923.
|
| 616 |
Promoter methylation induced epigenetic silencing of DAZAP2, a downstream effector of p38/MAPK pathway, in multiple myeloma cells.Cell Signal. 2019 Aug;60:136-145. doi: 10.1016/j.cellsig.2019.04.012. Epub 2019 Apr 26.
|
| 617 |
Effects of miR?81a on the biological function of multiple myeloma.Oncol Rep. 2019 Jul;42(1):291-300. doi: 10.3892/or.2019.7160. Epub 2019 May 15.
|
| 618 |
Modulation of cereblon levels by anti-myeloma agents.Leuk Lymphoma. 2016;57(1):167-76. doi: 10.3109/10428194.2015.1037752. Epub 2015 May 12.
|
| 619 |
Germline factor DDX4 functions in blood-derived cancer cell phenotypes.Cancer Sci. 2017 Aug;108(8):1612-1619. doi: 10.1111/cas.13299. Epub 2017 Jul 11.
|
| 620 |
A der(1;15)(q10;q10) is a rare nonrandom whole-arm translocation in patients with acute lymphoblastic leukemia.Cancer Genet Cytogenet. 2007 Dec;179(2):132-5. doi: 10.1016/j.cancergencyto.2007.08.008.
|
| 621 |
The RNA Exosome and Human Disease.Methods Mol Biol. 2020;2062:3-33. doi: 10.1007/978-1-4939-9822-7_1.
|
| 622 |
High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma.J Clin Pathol. 2006 Sep;59(9):947-51. doi: 10.1136/jcp.2005.031377. Epub 2006 Feb 17.
|
| 623 |
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.Nat Commun. 2015 May 26;6:7213. doi: 10.1038/ncomms8213.
|
| 624 |
Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells.Tumour Biol. 2017 Jun;39(6):1010428317703941. doi: 10.1177/1010428317703941.
|
| 625 |
Cytogenetic data as a prognostic factor in multiple myeloma patients: involvement of 1p12 region an adverse prognostic factor.Anticancer Res. 2004 Nov-Dec;24(6):4141-6.
|
| 626 |
Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas.PLoS One. 2010 May 21;5(5):e10755. doi: 10.1371/journal.pone.0010755.
|
| 627 |
Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy.Cancer Res. 2009 Feb 15;69(4):1545-52. doi: 10.1158/0008-5472.CAN-08-3858. Epub 2009 Feb 3.
|
| 628 |
A new multiple myeloma cell line, MEF-1, possesses cyclin D1 overexpression and the p53 mutation.Cancer. 1999 Apr 15;85(8):1750-7. doi: 10.1002/(sici)1097-0142(19990415)85:8<1750::aid-cncr15>3.0.co;2-5.
|
| 629 |
A possible role for the loss of CD27-CD70 interaction in myelomagenesis.Br J Haematol. 2003 Jan;120(2):223-34. doi: 10.1046/j.1365-2141.2003.04069.x.
|
| 630 |
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.Blood. 2007 Jul 15;110(2):709-18. doi: 10.1182/blood-2006-10-052845. Epub 2007 Mar 23.
|
| 631 |
Panobinostat for the Treatment of Multiple Myeloma.Clin Cancer Res. 2015 Nov 1;21(21):4767-73. doi: 10.1158/1078-0432.CCR-15-0530. Epub 2015 Sep 11.
|
| 632 |
SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma.Nat Cell Biol. 2013 Jan;15(1):72-81. doi: 10.1038/ncb2651.
|
| 633 |
PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.Blood. 2010 Sep 2;116(9):1460-8. doi: 10.1182/blood-2009-06-222943. Epub 2010 May 26.
|
| 634 |
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.Blood Cancer J. 2019 Feb 4;9(2):17. doi: 10.1038/s41408-019-0178-8.
|
| 635 |
In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by 41 cytoplasmic-binding proteins.Leukemia. 2016 Apr;30(4):861-72. doi: 10.1038/leu.2015.332. Epub 2015 Dec 10.
|
| 636 |
Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells.Br J Haematol. 2010 Apr;149(2):221-30. doi: 10.1111/j.1365-2141.2009.08070.x. Epub 2010 Jan 20.
|
| 637 |
Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease.Leuk Lymphoma. 2014 Apr;55(4):911-9. doi: 10.3109/10428194.2013.820288. Epub 2013 Aug 5.
|
| 638 |
Engraftment of gene-marked hematopoietic progenitors in myeloma patients after transplant of autologous long-term marrow cultures.Hum Gene Ther. 1999 Aug 10;10(12):1953-64. doi: 10.1089/10430349950017310.
|
| 639 |
Identification potential biomarkers and therapeutic agents in multiple myeloma based on bioinformatics analysis.Eur Rev Med Pharmacol Sci. 2016 Mar;20(5):810-7.
|
| 640 |
Expression and chromosomal localization of the gene for the human transcriptional repressor GCF.J Biol Chem. 1992 Jan 25;267(3):1689-94.
|
| 641 |
MiRNAs with prognostic significance in multiple myeloma: A systemic review and meta-analysis.Medicine (Baltimore). 2019 Aug;98(33):e16711. doi: 10.1097/MD.0000000000016711.
|
| 642 |
Silencing of augmenter of liver regeneration inhibited cell proliferation and triggered apoptosis in U266 human multiple myeloma cells.Braz J Med Biol Res. 2017 Aug 31;50(10):e6139. doi: 10.1590/1414-431X20176139.
|
| 643 |
Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis.J Hematol Oncol. 2018 Oct 4;11(1):123. doi: 10.1186/s13045-018-0666-5.
|
| 644 |
In Vivo Evaluation of Isoprenoid Triazole Bisphosphonate Inhibitors of Geranylgeranyl Diphosphate Synthase: Impact of Olefin Stereochemistry on Toxicity and Biodistribution.J Pharmacol Exp Ther. 2019 Nov;371(2):327-338. doi: 10.1124/jpet.119.258624. Epub 2019 Aug 16.
|
| 645 |
Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828.Anticancer Drugs. 2004 Jan;15(1):45-54. doi: 10.1097/00001813-200401000-00008.
|
| 646 |
A role for activator of G-protein signaling 3 (AGS3) in multiple myeloma.Int J Hematol. 2014 Jan;99(1):57-68. doi: 10.1007/s12185-013-1484-8. Epub 2013 Dec 5.
|
| 647 |
Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer.PLoS One. 2014 Jun 20;9(6):e100691. doi: 10.1371/journal.pone.0100691. eCollection 2014.
|
| 648 |
Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients.Blood. 2002 Oct 1;100(7):2578-85. doi: 10.1182/blood-2002-01-0030.
|
| 649 |
Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.Oncotarget. 2016 Aug 30;7(35):56013-56029. doi: 10.18632/oncotarget.10820.
|
| 650 |
Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DO as a novel target for multiple myeloma.Br J Haematol. 2013 Nov;163(3):343-51. doi: 10.1111/bjh.12544. Epub 2013 Aug 30.
|
| 651 |
Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa.PLoS One. 2017 Jan 4;12(1):e0169286. doi: 10.1371/journal.pone.0169286. eCollection 2017.
|
| 652 |
Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5.Oncoimmunology. 2018 Nov 2;8(2):e1534664. doi: 10.1080/2162402X.2018.1534664. eCollection 2019.
|
| 653 |
Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells.Leuk Lymphoma. 2008 Mar;49(3):559-69. doi: 10.1080/10428190701824544.
|
| 654 |
Cell adhesion downregulates the expression of Homer1b/c and contributes to drug resistance in multiple myeloma cells.Oncol Rep. 2016 Mar;35(3):1875-83. doi: 10.3892/or.2015.4532. Epub 2015 Dec 29.
|
| 655 |
Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations.Am J Hematol. 2011 Dec;86(12):E64-6. doi: 10.1002/ajh.22164. Epub 2011 Sep 22.
|
| 656 |
G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells.J Clin Invest. 2007 Oct;117(10):3107-17. doi: 10.1172/JCI31122.
|
| 657 |
Potential role of insulin-like growth factor binding protein-4 in the uncoupling of bone turnover in multiple myeloma.Br J Haematol. 1999 Mar;104(4):715-22. doi: 10.1046/j.1365-2141.1999.01243.x.
|
| 658 |
A phenylphthalimide derivative, TC11, induces apoptosis by degrading MCL1 in multiple myeloma cells.Biochem Biophys Res Commun. 2020 Jan 1;521(1):252-258. doi: 10.1016/j.bbrc.2019.10.119. Epub 2019 Oct 22.
|
| 659 |
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.Haematologica. 2012 Sep;97(9):1348-56. doi: 10.3324/haematol.2011.056747. Epub 2012 Mar 14.
|
| 660 |
The role of IL-3 in bone.J Cell Biochem. 2019 May;120(5):6851-6859. doi: 10.1002/jcb.27956. Epub 2018 Oct 15.
|
| 661 |
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma.Cancer Cell. 2017 Jul 10;32(1):88-100.e6. doi: 10.1016/j.ccell.2017.05.011. Epub 2017 Jun 29.
|
| 662 |
Dioncophyllines C(2), D(2), and F and Related Naphthylisoquinoline Alkaloids from the Congolese Liana Ancistrocladus ileboensis with Potent Activities against Plasmodium falciparum and against Multiple Myeloma and Leukemia Cell Lines.J Nat Prod. 2017 Feb 24;80(2):443-458. doi: 10.1021/acs.jnatprod.6b00967. Epub 2017 Jan 25.
|
| 663 |
PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.Oncogene. 2002 Aug 8;21(34):5289-300. doi: 10.1038/sj.onc.1205650.
|
| 664 |
Early tumor-cell gene expression changes may predict the response to first-line bortezomib-based therapy in patients with newly diagnosed multiple myeloma.J BUON. 2015 Sep-Oct;20(5):1314-21.
|
| 665 |
Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?.Neoplasia. 2019 Jan;21(1):93-105. doi: 10.1016/j.neo.2018.10.011. Epub 2018 Dec 5.
|
| 666 |
Constitutively expressed Oct-2 prevents immunoglobulin gene silencing in myeloma x T cell hybrids.Immunity. 1994 Nov;1(8):623-34. doi: 10.1016/1074-7613(94)90034-5.
|
| 667 |
Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region.Tumour Biol. 2010 Jan;31(1):33-45. doi: 10.1007/s13277-009-0005-0. Epub 2009 Dec 18.
|
| 668 |
UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.Cell Rep. 2017 Oct 17;21(3):628-640. doi: 10.1016/j.celrep.2017.09.078.
|
| 669 |
Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma.Blood. 2010 Sep 23;116(12):2033-9. doi: 10.1182/blood-2010-03-273706. Epub 2010 Jun 18.
|
| 670 |
LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma.Cell Death Dis. 2017 Aug 10;8(8):e2975. doi: 10.1038/cddis.2017.358.
|
| 671 |
Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells.PLoS One. 2018 Feb 12;13(2):e0192839. doi: 10.1371/journal.pone.0192839. eCollection 2018.
|
| 672 |
Differential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma.Mol Cancer. 2010 Sep 16;9:247. doi: 10.1186/1476-4598-9-247.
|
| 673 |
Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation.Clin Cancer Res. 2012 Jul 1;18(13):3697-704. doi: 10.1158/1078-0432.CCR-12-0191. Epub 2012 Apr 26.
|
| 674 |
Inactivation of the E3/LAPTm5 gene by chromosomal rearrangement and DNA methylation in human multiple myeloma.Leukemia. 2003 Aug;17(8):1650-7. doi: 10.1038/sj.leu.2403026.
|
| 675 |
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.Nat Genet. 2013 Oct;45(10):1221-1225. doi: 10.1038/ng.2733. Epub 2013 Aug 18.
|
| 676 |
Activation of LTBP3 gene by a long noncoding RNA (lncRNA) MALAT1 transcript in mesenchymal stem cells from multiple myeloma.J Biol Chem. 2014 Oct 17;289(42):29365-75. doi: 10.1074/jbc.M114.572693. Epub 2014 Sep 3.
|
| 677 |
MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.BMC Cancer. 2018 Jul 6;18(1):724. doi: 10.1186/s12885-018-4602-4.
|
| 678 |
Expression of hsa-MIR-204, RUNX2, PPAR, and BCL2 in Bone Marrow Derived Mesenchymal Stem Cells from Multiple Myeloma Patients and Normal Individuals.Cell J. 2017 Spring;19(Suppl 1):27-36. doi: 10.22074/cellj.2017.4480. Epub 2017 May 17.
|
| 679 |
Neither P-gp SNP variants, P-gp expression nor functional P-gp activity predicts MDR in a preliminary study of plasma cell myeloma.Cytometry B Clin Cytom. 2012 Jul;82(4):229-37. doi: 10.1002/cyto.b.21018. Epub 2012 Mar 29.
|
| 680 |
Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a coexpression of kappa and lambda light chains.Int J Clin Exp Pathol. 2015 Jul 1;8(7):8536-44. eCollection 2015.
|
| 681 |
Skeletrophin, a novel ubiquitin ligase to the intracellular region of Jagged-2, is aberrantly expressed in multiple myeloma.Am J Pathol. 2005 Jun;166(6):1817-26. doi: 10.1016/S0002-9440(10)62491-1.
|
| 682 |
Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences.Blood. 2007 Sep 15;110(6):1797-805. doi: 10.1182/blood-2006-06-032938. Epub 2007 May 31.
|
| 683 |
Human beta-defensin-1 and -2 and matrix metalloproteinase-25 and -26 expression in chronic and aggressive periodontitis and in peri-implantitis.Arch Oral Biol. 2008 Feb;53(2):175-86. doi: 10.1016/j.archoralbio.2007.09.010. Epub 2007 Nov 9.
|
| 684 |
Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants.Blood. 2003 Feb 15;101(4):1570-1. doi: 10.1182/blood-2002-08-2436. Epub 2002 Oct 3.
|
| 685 |
Aberrant promoter methylation of p15 (INKb) and p16 (INKa) genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis.Tumour Biol. 2014 Sep;35(9):9035-43. doi: 10.1007/s13277-014-2054-2. Epub 2014 Jun 8.
|
| 686 |
Acquisition of resistance toward HYD1 correlates with a reduction in cleaved 4 integrin expression and a compromised CAM-DR phenotype.Mol Cancer Ther. 2011 Dec;10(12):2257-66. doi: 10.1158/1535-7163.MCT-11-0149. Epub 2011 Oct 6.
|
| 687 |
Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro.Blood. 1994 Nov 1;84(9):3026-33.
|
| 688 |
Therapeutic Advances in the Management of Smoldering Myeloma.Am J Ther. 2020 Mar/Apr;27(2):e194-e203. doi: 10.1097/MJT.0000000000001034.
|
| 689 |
Effects of TNF, NOS3, MDR1 Gene Polymorphisms on Clinical Parameters, Prognosis and Survival of Multiple Myeloma Cases.Asian Pac J Cancer Prev. 2016;17(3):1009-14. doi: 10.7314/apjcp.2016.17.3.1009.
|
| 690 |
Aberrant expression of napsin A in a subset of malignant lymphomas.Histol Histopathol. 2016 Feb;31(2):213-21. doi: 10.14670/HH-11-669. Epub 2015 Sep 24.
|
| 691 |
Loss of the SMRT/NCoR2 corepressor correlates with JAG2 overexpression in multiple myeloma.Cancer Res. 2009 May 15;69(10):4380-7. doi: 10.1158/0008-5472.CAN-08-3467. Epub 2009 May 5.
|
| 692 |
Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.Oncotarget. 2014 Sep 30;5(18):8284-305. doi: 10.18632/oncotarget.2058.
|
| 693 |
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.Blood. 2007 Feb 15;109(4):1692-700. doi: 10.1182/blood-2006-07-037077. Epub 2006 Oct 5.
|
| 694 |
NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.Nat Cell Biol. 2007 Jul;9(7):804-12. doi: 10.1038/ncb1608. Epub 2007 Jun 24.
|
| 695 |
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.Blood. 2009 Oct 8;114(15):3276-84. doi: 10.1182/blood-2009-04-219436. Epub 2009 Jul 8.
|
| 696 |
Novel ORC4L gene mutation in B-cell lymphoproliferative disorders.Am J Med Sci. 2009 Dec;338(6):527-9. doi: 10.1097/MAJ.0b013e3181b7f17c.
|
| 697 |
Doxorubicin-Loaded PEG-CdTe Quantum Dots as a Smart Drug Delivery System for Extramedullary Multiple Myeloma Treatment.Nanoscale Res Lett. 2018 Nov 22;13(1):373. doi: 10.1186/s11671-018-2782-0.
|
| 698 |
MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants.Br J Haematol. 2003 Aug;122(3):430-40. doi: 10.1046/j.1365-2141.2003.04455.x.
|
| 699 |
Research Progress on PARP14 as a Drug Target.Front Pharmacol. 2019 Mar 5;10:172. doi: 10.3389/fphar.2019.00172. eCollection 2019.
|
| 700 |
DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.Leukemia. 2010 Nov;24(11):1951-9. doi: 10.1038/leu.2010.196. Epub 2010 Sep 23.
|
| 701 |
miR-320a regulates cell proliferation and apoptosis in multiple myeloma by targeting pre-B-cell leukemia transcription factor 3.Biochem Biophys Res Commun. 2016 May 13;473(4):1315-1320. doi: 10.1016/j.bbrc.2016.04.069. Epub 2016 Apr 14.
|
| 702 |
PCDH10 inhibits cell proliferation of multiple myeloma via the negative regulation of the Wnt/-catenin/BCL-9 signaling pathway.Oncol Rep. 2015 Aug;34(2):747-54. doi: 10.3892/or.2015.4056. Epub 2015 Jun 11.
|
| 703 |
NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.Cancer Res. 2013 Oct 15;73(20):6277-88. doi: 10.1158/0008-5472.CAN-13-1000. Epub 2013 Aug 26.
|
| 704 |
Establishment of stable multiple myeloma cell line with overexpressed PDCD5 and its proapoptosis mechanism.Int J Clin Exp Pathol. 2015 Sep 1;8(9):10635-43. eCollection 2015.
|
| 705 |
MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFB Activation in Breast Cancer.Mol Cancer Ther. 2015 Jun;14(6):1454-65. doi: 10.1158/1535-7163.MCT-14-1053. Epub 2015 Apr 2.
|
| 706 |
A quantitative analysis of genomic instability in lymphoid and plasma cell neoplasms based on the PIG-A gene.Mutat Res. 2010 Apr 1;686(1-2):1-8. doi: 10.1016/j.mrfmmm.2009.11.012. Epub 2010 Jan 8.
|
| 707 |
Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer.Expert Opin Ther Targets. 2017 Aug;21(8):767-779. doi: 10.1080/14728222.2017.1349754. Epub 2017 Jul 18.
|
| 708 |
TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.Blood. 2017 Mar 9;129(10):1284-1295. doi: 10.1182/blood-2016-09-737536. Epub 2017 Jan 4.
|
| 709 |
In silico analysis identifies CRISP3 as a potential peripheral blood biomarker for multiple myeloma: From data modeling to validation with RT-PCR.Oncol Lett. 2018 Apr;15(4):5167-5174. doi: 10.3892/ol.2018.7969. Epub 2018 Feb 6.
|
| 710 |
Disulfiram/copper targets stem cell-like ALDH(+) population of multiple myeloma by inhibition of ALDH1A1 and Hedgehog pathway.J Cell Biochem. 2018 Aug;119(8):6882-6893. doi: 10.1002/jcb.26885. Epub 2018 Apr 17.
|
| 711 |
Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations.Jpn J Cancer Res. 2001 Jun;92(6):638-44. doi: 10.1111/j.1349-7006.2001.tb01142.x.
|
| 712 |
Effects of epigenetic-based anti-cancer drugs in leukaemia and multiple myeloma cells.Cell Biol Int. 2011 Dec;35(12):1195-203. doi: 10.1042/CBI20100820.
|
| 713 |
Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells.Cell Death Differ. 2016 Jul;23(7):1175-84. doi: 10.1038/cdd.2015.167. Epub 2016 Jan 29.
|
| 714 |
Prokineticin-1/endocrine gland-derived vascular endothelial growth factor is a survival factor for human multiple myeloma cells.Leuk Lymphoma. 2010 Oct;51(10):1902-12. doi: 10.3109/10428194.2010.512963.
|
| 715 |
The G-Allele of the PSMA6-8C>G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levels.Eur J Haematol. 2010 Aug;85(2):108-13. doi: 10.1111/j.1600-0609.2010.01455.x. Epub 2010 Apr 8.
|
| 716 |
Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma.Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):734-742. doi: 10.1016/j.clml.2017.06.034. Epub 2017 Jun 30.
|
| 717 |
PSMB4 promotes multiple myeloma cell growth by activating NF-B-miR-21 signaling.Biochem Biophys Res Commun. 2015 Mar 6;458(2):328-33. doi: 10.1016/j.bbrc.2015.01.110. Epub 2015 Feb 3.
|
| 718 |
CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma.Mol Cancer Ther. 2017 Dec;16(12):2862-2870. doi: 10.1158/1535-7163.MCT-17-0130. Epub 2017 Sep 27.
|
| 719 |
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.Blood. 2011 Sep 29;118(13):3512-24. doi: 10.1182/blood-2010-12-328252. Epub 2011 May 31.
|
| 720 |
Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis.Br J Haematol. 2008 Jan;140(1):25-35. doi: 10.1111/j.1365-2141.2007.06871.x. Epub 2007 Nov 12.
|
| 721 |
Expression of parathyroid hormone-related protein (PTHrP) in multiple myeloma.Pathol Int. 2002 Jan;52(1):63-8. doi: 10.1046/j.1440-1827.2002.01314.x.
|
| 722 |
NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27.Oncotarget. 2017 May 23;8(21):35088-35102. doi: 10.18632/oncotarget.17070.
|
| 723 |
Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).Hematol Oncol. 2018 Feb;36(1):62-67. doi: 10.1002/hon.2472. Epub 2017 Aug 22.
|
| 724 |
Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma.Bone Marrow Transplant. 2019 Apr;54(4):587-594. doi: 10.1038/s41409-018-0302-6. Epub 2018 Aug 16.
|
| 725 |
Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin-6-responsive multiple myeloma KAS-6/1 cells.J Biol Chem. 2005 Feb 11;280(6):4182-7. doi: 10.1074/jbc.M412566200. Epub 2004 Nov 17.
|
| 726 |
Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma.Blood. 2010 Jan 21;115(3):601-4. doi: 10.1182/blood-2009-02-204396. Epub 2009 Nov 13.
|
| 727 |
Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.Clin Cancer Res. 2009 Jul 1;15(13):4356-64. doi: 10.1158/1078-0432.CCR-08-3336. Epub 2009 Jun 23.
|
| 728 |
Plasma cell labeling index correlates with deletion of 13q14 in multiple myeloma.Leuk Lymphoma. 2011 Feb;52(2):260-4. doi: 10.3109/10428194.2010.538775. Epub 2010 Dec 6.
|
| 729 |
RBQ3 participates in multiple myeloma cell proliferation, adhesion and chemoresistance.Int J Biol Macromol. 2016 Oct;91:115-22. doi: 10.1016/j.ijbiomac.2016.05.050. Epub 2016 May 14.
|
| 730 |
The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease.Tissue Antigens. 2008 Jun;71(6):548-51. doi: 10.1111/j.1399-0039.2008.01048.x. Epub 2008 Apr 7.
|
| 731 |
Extracellular matrix protein Reelin promotes myeloma progression by facilitating tumor cell proliferation and glycolysis.Sci Rep. 2017 Mar 27;7:45305. doi: 10.1038/srep45305.
|
| 732 |
Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma.Oncogene. 2000 Apr 13;19(16):2023-32. doi: 10.1038/sj.onc.1203521.
|
| 733 |
Proteomic Characterization of the World Trade Center dust-activated mdig and c-myc signaling circuit linked to multiple myeloma.Sci Rep. 2016 Nov 11;6:36305. doi: 10.1038/srep36305.
|
| 734 |
RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses.Mol Cancer Ther. 2010 Nov;9(11):3041-51. doi: 10.1158/1535-7163.MCT-10-0471. Epub 2010 Nov 9.
|
| 735 |
Knockdown of macrophage inhibitory cytokine-1 in RPMI-8226 human multiple myeloma cells inhibits osteoclastic differentiation through inhibiting the RANKL-Erk1/2 signaling pathway.Mol Med Rep. 2016 Dec;14(6):5199-5204. doi: 10.3892/mmr.2016.5879. Epub 2016 Oct 24.
|
| 736 |
Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma.Br J Haematol. 2017 Sep;178(5):781-793. doi: 10.1111/bjh.14771. Epub 2017 Jun 9.
|
| 737 |
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.Blood. 2017 Sep 7;130(10):1189-1197. doi: 10.1182/blood-2017-03-775122. Epub 2017 May 1.
|
| 738 |
Identification and expression of MMSA-8, and its clinical significance in multiple myeloma.Oncol Rep. 2017 Jun;37(6):3235-3243. doi: 10.3892/or.2017.5609. Epub 2017 Apr 28.
|
| 739 |
Multiple myeloma cells' capacity to decompose H(2)O(2) determines lenalidomide sensitivity.Blood. 2017 Feb 23;129(8):991-1007. doi: 10.1182/blood-2016-09-738872. Epub 2016 Dec 27.
|
| 740 |
Classical Hodgkin's lymphoma shows epigenetic features of abortive plasma cell differentiation.Haematologica. 2011 Jun;96(6):863-70. doi: 10.3324/haematol.2010.031138. Epub 2011 Mar 10.
|
| 741 |
Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.Leuk Res. 2013 Aug;37(8):963-9. doi: 10.1016/j.leukres.2013.03.004. Epub 2013 Mar 26.
|
| 742 |
Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma.Clin Cancer Res. 2009 Sep 1;15(17):5369-78. doi: 10.1158/1078-0432.CCR-09-0040. Epub 2009 Aug 18.
|
| 743 |
Pattern of gene expression and immune responses to Semenogelin 1 in chronic hematologic malignancies.J Immunother. 2003 Nov-Dec;26(6):461-7. doi: 10.1097/00002371-200311000-00001.
|
| 744 |
Metabolism of thyroxine-binding globulin in man. Abnormal rate of synthesis in inherited thyroxine-binding globulin deficiency and excess.J Clin Invest. 1976 Feb;57(2):485-95. doi: 10.1172/JCI108301.
|
| 745 |
Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity.Mol Cell Biol. 2008 Mar;28(6):2023-34. doi: 10.1128/MCB.02130-07. Epub 2008 Jan 2.
|
| 746 |
Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis.Int J Hematol. 2012 Oct;96(4):492-500. doi: 10.1007/s12185-012-1171-1. Epub 2012 Sep 13.
|
| 747 |
Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma.Cancer Lett. 2009 Aug 18;281(1):24-31. doi: 10.1016/j.canlet.2009.02.002. Epub 2009 Mar 18.
|
| 748 |
Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines.PLoS One. 2015 Apr 2;10(4):e0122689. doi: 10.1371/journal.pone.0122689. eCollection 2015.
|
| 749 |
Growth Factor-like Gene Regulation Is Separable from Survival and Maturation in Antibody-Secreting Cells.J Immunol. 2019 Feb 15;202(4):1287-1300. doi: 10.4049/jimmunol.1801407. Epub 2019 Jan 14.
|
| 750 |
The role of SH3GL3 in myeloma cell migration/invasion, stemness and chemo-resistance.Oncotarget. 2016 Nov 8;7(45):73101-73113. doi: 10.18632/oncotarget.12231.
|
| 751 |
Human herpesvirus 8 open reading frame 26 and open reading frame 65 sequences from multiple myeloma patients: a shared pattern not found in Kaposi's sarcoma or primary effusion lymphoma.Clin Cancer Res. 2000 Nov;6(11):4226-33.
|
| 752 |
Quantitative superresolution microscopy reveals differences in nuclear DNA organization of multiple myeloma and monoclonal gammopathy of undetermined significance.J Cell Biochem. 2015 May;116(5):704-10. doi: 10.1002/jcb.25030.
|
| 753 |
Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.Blood. 2011 Feb 10;117(6):1947-57. doi: 10.1182/blood-2010-06-291146. Epub 2010 Dec 10.
|
| 754 |
Clinical impact of serum soluble SLAMF7 in multiple myeloma.Oncotarget. 2018 Oct 5;9(78):34784-34793. doi: 10.18632/oncotarget.26196. eCollection 2018 Oct 5.
|
| 755 |
Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma.PLoS One. 2017 Apr 3;12(4):e0174835. doi: 10.1371/journal.pone.0174835. eCollection 2017.
|
| 756 |
Differential oncogene-related gene expressions in myeloma cells resistant to prednisone and vincristine.Biomed Pharmacother. 2012 Oct;66(7):506-11. doi: 10.1016/j.biopha.2012.02.007. Epub 2012 May 9.
|
| 757 |
Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse.Oncotarget. 2016 Dec 6;7(49):80664-80679. doi: 10.18632/oncotarget.13025.
|
| 758 |
Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms.Mod Pathol. 2010 Jan;23(1):105-12. doi: 10.1038/modpathol.2009.140. Epub 2009 Oct 2.
|
| 759 |
SPAN-Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically.Int J Cancer. 2006 Mar 15;118(6):1436-44. doi: 10.1002/ijc.21499.
|
| 760 |
Cell adhesion to fibronectin down-regulates the expression of Spy1 and contributes to drug resistance in multiple myeloma cells.Int J Hematol. 2013 Oct;98(4):446-55. doi: 10.1007/s12185-013-1435-4. Epub 2013 Sep 14.
|
| 761 |
Increased expression of miR-27 predicts poor prognosis and promotes tumorigenesis in human multiple myeloma.Biosci Rep. 2019 Apr 9;39(4):BSR20182502. doi: 10.1042/BSR20182502. Print 2019 Apr 30.
|
| 762 |
shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines.Int J Clin Exp Pathol. 2015 Mar 1;8(3):2300-10. eCollection 2015.
|
| 763 |
SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.J Immunother. 2005 Nov-Dec;28(6):564-75. doi: 10.1097/01.cji.0000175685.36239.e5.
|
| 764 |
The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma.Blood. 2014 Sep 11;124(11):1765-76. doi: 10.1182/blood-2014-03-560862. Epub 2014 Jul 24.
|
| 765 |
Syntaxin-4 is essential for IgE secretion by plasma cells.Biochem Biophys Res Commun. 2013 Oct 11;440(1):163-7. doi: 10.1016/j.bbrc.2013.09.058. Epub 2013 Sep 18.
|
| 766 |
Association of TAP1 and TAP2 gene polymorphisms with hematological malignancies.Asian Pac J Cancer Prev. 2013;14(9):5213-7. doi: 10.7314/apjcp.2013.14.9.5213.
|
| 767 |
Investigation of copy-number variations of C8orf4 in hematological malignancies.Med Oncol. 2011 Dec;28 Suppl 1:S647-52. doi: 10.1007/s12032-010-9698-6. Epub 2010 Sep 29.
|
| 768 |
Elevated expression of APE1/Ref-1 and its regulation on IL-6 and IL-8 in bone marrow stromal cells of multiple myeloma.Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):385-93. doi: 10.3816/CLML.2010.n.072.
|
| 769 |
The potential functions of FAM46C in oral squamous cell carcinoma.Onco Targets Ther. 2018 Dec 10;11:8915-8923. doi: 10.2147/OTT.S185244. eCollection 2018.
|
| 770 |
Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma.Br J Haematol. 2007 Sep;138(6):756-60. doi: 10.1111/j.1365-2141.2007.06729.x.
|
| 771 |
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4.
|
| 772 |
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.Cancer Cell. 2016 May 9;29(5):639-652. doi: 10.1016/j.ccell.2016.03.026. Epub 2016 Apr 28.
|
| 773 |
Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB.Br J Haematol. 2010 Sep;150(5):543-53. doi: 10.1111/j.1365-2141.2010.08284.x. Epub 2010 Jul 14.
|
| 774 |
Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types.Int J Cancer. 2004 May 1;109(5):786-92. doi: 10.1002/ijc.20041.
|
| 775 |
Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma.Leukemia. 2009 Oct;23(10):1913-9. doi: 10.1038/leu.2009.129. Epub 2009 Aug 6.
|
| 776 |
B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.Exp Hematol. 2007 Mar;35(3):443-53. doi: 10.1016/j.exphem.2006.11.002.
|
| 777 |
The oncogenic membrane protein LMP1 sequesters TRAF3 in B-cell lymphoma cells to produce functional TRAF3 deficiency.Blood Adv. 2017 Dec 18;1(27):2712-2723. doi: 10.1182/bloodadvances.2017009670. eCollection 2017 Dec 26.
|
| 778 |
An integrated bioinformatical analysis of miR-19a target genes in multiple myeloma.Exp Ther Med. 2017 Nov;14(5):4711-4720. doi: 10.3892/etm.2017.5173. Epub 2017 Sep 21.
|
| 779 |
Interferon regulatory factor 4 (IRF-4) targets IRF-5 to regulate Epstein-Barr virus transformation.J Biol Chem. 2011 May 20;286(20):18261-7. doi: 10.1074/jbc.M110.210542. Epub 2011 Mar 24.
|
| 780 |
Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma.J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):244-54. doi: 10.1016/j.jsbmb.2007.11.003. Epub 2008 Apr 20.
|
|
|
|
|
|
|
